

# Leveraging Family History and Age-of-Onset to Boost GWAS Power and Disorder Prediction

PhD dissertation

Emil Michael Pedersen

Health  
Aarhus University  
2022



# Leveraging Family History and Age-of-Onset Information to Estimate Disease Liability and Improve Power in GWAS

PhD dissertation

Emil Michael Pedersen

Health  
Aarhus University  
National Centre for Register-based Research

# Acknowledgements

The work presented in this dissertation was carried out during my employment at the National Centre for Register-based Research (NCRR), Aarhus BSS, Aarhus University, while being enrolled at the Aarhus University Graduate School of Health. The work was funded in part by the Niels Bohr professorship to John McGrath and in part by the Graduate School of Health.

First, I would like to thank my supervisors. Bjarni Jóhann Vilhjálmsson for introducing me to the field of statistical genetics and agreeing to be my main supervisor for this PhD. Florian Franck Privé for sharing his extensive knowledge about R and statistics and helping me become a far better programmer. Esben Agerbo for his insight and encouragements. I would also like to thank all my supervisors for the many discussions and always being able to find time for me. In particular, I appreciate the support I received during the difficult times with lockdowns during the Covid pandemic.

I would also like to thank Mark Daly for inviting me to come work with FinnGen data for a time. I found it very interesting and I hope to do similar things in the future. Thank you to Andrea Ganna for hosting me during my stay in Finland and allowing me to be part of his excellent group at FIMM.

Thank you to all my NCRR colleagues, both new and old, that have made working at NCRR an absolute joy. A particular thank you to Clara Albiñana for starting her PhD journey alongside mine. It has been an incredible experience to have someone to go on this journey with. Finally, I would also like to thank my family and friends for being supportive and encouraging me during the entire PhD.

Emil Michael Pedersen  
Aarhus, December 2022

# Abbreviations

<b>ADHD</b>	Attention deficit hyperactivity disorder
<b>ADuLT</b>	Age dependent liability threshold
<b>CDF</b>	Cumulative Distribution Function
<b>CIP</b>	Cumulative incidence proportion
<b>GRM</b>	Genomic Relationship Matrix
<b>GWAS</b>	Genome-wide association study
<b>GWAX</b>	Genome-wide association study by proxy
<b>ICD-8</b>	The international statistical classification of diseases and related health problems, 8th revision
<b>ICD-10</b>	The international statistical classification of diseases and related health problems, 10th revision
<b>iPSYCH</b>	The Lundbeck foundation initiative for integrative psychiatric research
<b>IPW</b>	Inverse Probability Weighing
<b>LTM</b>	Liability threshold model
<b>LT-FH</b>	Liability threshold model conditional on family history
<b>LT-FH++</b>	Extended LT-FH
<b>MAC</b>	Minor Allele Count
<b>PC</b>	Principal Component
<b>PCA</b>	Principal Component Analysis
<b>PH</b>	Proportional hazards
<b>PRS</b>	Polygenic risk score
<b>SNP</b>	Single nucleotide polymorphism
<b>SPA</b>	Saddle Point Approximation

# List of Papers

The dissertation is based on the following papers. They are presented in the order of publication.

## Paper 1

EM Pedersen, E Agerbo, O Plana-Ripoll, J Grove, JW Dreier, KL Musliner, M Bækvad-Hansen, G Athanasiadis, A Schork, D Demontis, J Bybjerg-Grauholm, DM Hougaard, T Werge, M Nordentoft, O Mors, S Dalsgaard, J Christensen, AD Børglum, PB Mortensen, JJ McGrath, F Privé, BJ Vilhjálmsón. Accounting for age-of-onset and family history improves power in genome-wide association studies. *American Journal of Human Genetics*, 109: 417-432.

## Paper 2

EM Pedersen, E Agerbo, O Plana-Ripoll, J Steinbach, MD Krebs, DM Hougaard, T Werge, M Nordentoft, A Børglum, KL Musliner, A Ganna, AJ Schork, PB Mortensen, JJ McGrath, F Privé, BJ Vilhjálmsón. ADuLT: An efficient and robust time-to-event GWAS. *medRxiv*, doi: <https://doi.org/10.1101/2022.08.11.22278618> [Under review]

## Paper 3

**Study 3:** fGRS and fGRS multi trait [TBD - Under construction]

Besides these I have contributed to several other manuscripts that are not included in this dissertation. This includes the three published studies and one pre-print.

1. MJ Witteveen, EM Pedersen, J Meijssen, MR Andersen, F Privé, D Speed, and BJ Vilhjálmsón. Publicly Available Privacy-preserving Benchmarks for Polygenic Prediction. *bioRxiv*, <https://doi.org/10.1101/2022.10.10.510645>
2. T Wimberley, I Brikell, EM Pedersen, E Agerbo, BJ Vilhjálmsón, C Albiñana, F Privé, A Thapar, K Langley, L Riglin, M Simonsen, HS Nielsen, AD Børglum, M Nordentoft, PB Mortensen, S Dalsgaard. Early life injuries and the development of attention-deficit hyperactivity disorder. *Journal of Clinical Psychiatry*, doi:<https://doi.org/10.4088/JCP.21m14033>.
3. I Brikell, T Wimberley, C Albiñana, EM Pedersen, BJ Vilhjálmsón, E Agerbo, D Demontis, AD Børglum, A Schork, S LaBianca, T Werge, M Nordentoft, O Mors, D Hougaard, A Thapar, PB Mortensen, S Dalsgaard. Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD. *American Journal of Psychiatry*, doi:<https://doi.org/10.1176/appi.ajp.2020.20121686>.

4. X Liu, T Munk-Olsen, C Albiñana, BJ Vilhjálmsson, E Pedersen, V Schlünssen, M Bækvad-Hansen, J Bybjerg-Grauholm, M Nordentoft, A Børglum, T Werge, D Hougaard, PB Mortensen, E Agerbo. Genetic liability to major depression and risk of childhood asthma. *Brain Behavior and Immunity*, doi: <https://doi.org/10.1016/j.bbi.2020.07.030>.

# Contents

<b>1</b>	<b>Introduction</b>	<b>1</b>
<b>2</b>	<b>Study Aims</b>	<b>5</b>
<b>3</b>	<b>Materials and Methods</b>	<b>6</b>
3.1	Data Sources . . . . .	6
3.1.1	Danish Registers . . . . .	6
3.1.2	Cumulative Incidence Proportions . . . . .	7
3.1.3	Genotype Data . . . . .	8
3.2	Genome-Wide Association Study . . . . .	10
3.2.1	Common GWAS Models . . . . .	10
3.2.2	Controlling Type-1 and Type-2 Errors . . . . .	12
3.2.3	Censoring . . . . .	14
3.2.4	Bias . . . . .	16
3.2.5	Computational Efficiency . . . . .	16
3.2.6	Increasing Power in GWAS . . . . .	20
3.2.7	Notable Methodological Advancements . . . . .	21
3.3	Liability Threshold Model, Family History & Age-of-Onset . . . . .	22
3.3.1	GWAX . . . . .	22
3.3.2	The Liability Threshold Model . . . . .	23
3.3.3	LT-FH . . . . .	23
3.3.4	LT-FH++ . . . . .	25
3.3.5	LT-FH++ with Correlated Traits . . . . .	28
3.3.6	LT-FH++ and Survival Analysis . . . . .	29
<b>4</b>	<b>Results</b>	<b>31</b>
4.1	Paper 1 - LT-FH++ . . . . .	31
4.1.1	Simulation Results . . . . .	31
4.1.2	Real-World Analysis . . . . .	33
4.2	Paper 2 - ADuLT . . . . .	34
4.2.1	Simulation Results . . . . .	34
4.2.2	Real-World Analysis . . . . .	36
4.3	Paper 3 - fGRS . . . . .	37
4.3.1	Real-World Analysis . . . . .	37



<b>5</b>	<b>Discussion</b>	<b>40</b>
5.1	Paper 1 - LT-FH++ . . . . .	40
5.2	Paper 2 - ADuLT . . . . .	41
5.3	Paper 3 - fGRS . . . . .	42
<b>6</b>	<b>Conclusion</b>	<b>43</b>
<b>7</b>	<b>Future Directions</b>	<b>45</b>
<b>8</b>	<b>English Abstract</b>	<b>46</b>
<b>9</b>	<b>Danish Abstract</b>	<b>47</b>
	<b>References</b>	<b>48</b>
	<b>Appendices</b>	<b>54</b>
<b>A</b>	<b>Study 1 - LT-FH++</b>	<b>55</b>
<b>B</b>	<b>Study 2 - ADuLT</b>	<b>57</b>

# Chapter 1

## Introduction

Over the couple of last decades, identifying genetic variants associated with diseases have been a major focus of research in human genetics; and for good reason. Identifying disease-associated single nucleotide polymorphisms (SNPs) or genes provides insight into the genetic architecture of diseases and their aetiology. Ultimately, improved understanding of the diseases can lead to novel treatments and development of preventive measures<sup>**todo: ref.**</sup> Although the field of genomics is still relatively young several promising discoveries have already been made. Some notable achievements include the development of genetic screening methods for disorders through a polygenic risk score (PRS), identification of risk-associated genes to target for drug development<sup>**TODO:refs.**</sup> In addition, those discoveries have shone light on the the aetiology of complex and polygenic disorders. Individual-level genotype data may further improve diagnoses and help identify more effective treatment options through precision medicine. A key method underlying these developments is the genome-wide association study (GWAS), which allows for the identification of SNPs and possible genes that are associated with a given phenotype. The detected SNPs can then be examined further with subsequent analysis and their risk contributions can be aggregated to construct a PRS<sup>**TODO:ref.**</sup> Therefore, it is important to continue to further improve GWAS methods and to increase the statistical power in GWAS settings.

Two primary methods that have been used to increase the statistical power of GWASs are to increase the sample size and to improve the methodology. As it is commonly not possible to share individual-level genotype data, the sample size has often been increased by meta-analysing GWASs from different cohorts. At the present time, several methods have been proposed to increase the amount of genetic heterogeneity captured between cohorts, such as inverse-variance weighted meta-analysis and random effect meta-analysis[1, 2]. The largest meta-analysis GWAS performed to date is of height with more than 5.4 million individuals[3]. Alongside the increased sample size, there have also been improvements regarding the methodology. These improvements have mainly been in connection to computational efficiency as well as the development of more powerful GWAS models.

As the field evolves, knowledge about various complexities of GWAS are being discovered. This involves concepts such as in-sample relatedness (also called cryptic relatedness), different genetic ancestries, and population stratification<sup>**todo:ref.**</sup> Initially, linear regression models were used to find associations in GWAS, but as these models are poorly suited to account for cryptic relatedness, differences in genetic ancestries, and population stratification, new models such as linear mixed models were proposed. BOLT-LMM[4] is an excellent example of an improvement that provided both computational efficiency and a more complex model. Prior to its publication, linear mixed models had a prohibitive computational cost, making them intractable for analysis

of more than 100,000 individuals.

Even though it is likely that further improvements regarding sample sizes and methodology will be made, it is also reasonable to consider related fields and their common practices, as the application of methods from other fields in human genetics has already lead to considerable improvements<sup>**todo:ref**</sup>. Animal genetics has many similarities with human genetics and some of the commonly used models and computational strategies from the field of animal genetics have already been applied to human genetics with great success<sup>**todo:ref**</sup>. As an example, some of the computational mechanisms employed by BOLT-LMM are based on methods commonly used in animal genetics, while the polygenic risk scores are heavily inspired by the genetic breeding value used in the same field.[4–6]. Prior to the increase in size of genotyped (and imputed) data, family history has been a commonly used and valuable predictor for many disorders in both epidemiology as well as animal and human genetics[7–10]. A well known application of family history as a predictor in human genetics can be seen in the Framingham, where it was used to improve risk assessment of heart disease[11, 12].

Unfortunately, family history is not commonly available with genetic data in biobanks. This has limited the development of methods that can utilise family history in a GWAS setting. There is a small, but fortunately an increasing, number of biobanks that provide some degree of family history with their genetic data. Among those biobanks are UK biobank (UKBB) [13], deCODE[14], iPSYCH[15], and FinnGen[16]. Even if the family history is available, there are big differences in coverage and origin of the information between biobanks. In UKBB, family history is only available for 12 disorders and it was obtained through questionnaires. It is therefore likely be prone to recall-bias. The iPSYCH sample has been linked to the Danish registers, which allows for the construction of near complete family trees from 1969 onwards. Genetic and phenotypic information is available for all individuals in the iPSYCH sample, while all recorded family members have phenotypic information. As the name indicates, FinnGen originates from Finland, which (like Denmark) is known for its detailed registers. However, FinnGen has only limited family history linked to the genetic data due to privacy concerns. At the present time, it has only been allowed to link the parental cause of death to the genetic data stored in FinnGen, even though far more information would be available in the Finish registers. Even though the adoption of family history by biobanks has been limited, the family history methods that have been developed so far have shown a tremendous amount of potential.

One of the first and most well-known family history methods that was developed is called genome-wide association study by proxy (GWAX)[17]. GWAX redefines the binary case-control phenotype such that cases also include controls with family history. Cases under the GWAX approach are therefore either affected themselves or have close family members that are. Liu et al., who proposed GWAX, analysed Alzheimer’s disease, which is a disorder with a low prevalence among the UKBB participants. Many of the participants are simply too young to have been diagnosed with Alzheimer’s disease at the time of censoring. However, their parents are old enough to have been diagnosed prior to censoring, and hence, GWAX increased the number of considered cases. For low prevalence or late onset disorders, it has been shown to be a powerful tool when trying to identify genome-wide significant SNPs[17–19]. As a result, GWAX has successfully provided a proof-of-concept and paved the way for other family history methods. However, GWAX also has a limitation, since it loses power if the in-sample prevalence is high ( $> 50\%$ ) for the GWAX phenotypet<sup>**todo:ref**</sup>. In addition, it is a heuristic method, which is not based on any model. Since GWAX was proposed, another method called the liability threshold model conditional on family history (LT-FH) has been introduced<sup>**todo:ref**</sup>. This method solves the two above mentioned limitations of GWAX. LT-FH is also the method that this dissertation have expanded further on to also allow for modelling of age-of-onset, sex, and cohort effects in the individual of interest and their considered family members. The extension we developed is

called LT-FH++**todo:ref**.

To the best of our knowledge, no other model accounts for family history *and* age-of-onset simultaneously. In terms of age-of-onset, an often favoured method is some variation of the Cox proportional hazards(PH) models. In fact, the Cox PH model and the frailty model are the only two survival models that have been regularly used in GWAS settings**todo:ref**. The frailty model is a generalisation of the Cox PH model that also includes a random effect that can be used to model the cryptic relatedness. Frailty models and mixed models share many advantages, as they are both able to account for cryptic relatedness in biobanks. However, the adoption of frailty models in connection to GWASs has been limited. One of the reasons for the slow adoption is likely due the computational complexity of the frailty models. Prior to the publication of the Cox PH model called SPACox in 2020 by Bi et al., a Cox PH based GWAS was limited to less than 100.000 individuals due to computational cost[20]. This is especially striking, as other computationally intensive models, such as linear mixed models, had been computationally feasible for more than 400.000 individuals since 2015 [4]. Frailty models were similarly computationally intractable for more than 20.000 individuals until 2022, where the method GATE was proposed[21]. Both SPACox and GATE utilise the saddle point approximation(SPA) as an efficient way of calculating p-values. SPA only requires the cumulant generating function of the test statistic to calculate p-values.

In this dissertation, we will focus on the development and applications of LT-FH++, which is based on the age-dependent liability threshold model (ADuLT)**todo:ref**. If family history is included, we will refer to the method as LT-FH++, and if only the index person is considered (that is, no family history), we will refer to it as ADuLT. LT-FH++ combines many of the concepts used in survival analysis and the Cox PH methods that have been developed for GWASs with family history. In short, LT-FH extends the classical liability threshold model(LTM) proposed by Falconer[22, 23] to incorporate family history, while LT-FH++ extends LT-FH to further include age-of-onset information. LT-FH++ accounts for age-of-onset by using a personalised threshold in the LTM, instead of the fixed threshold that is normally used in the LTM. Each threshold used to determine the case-control status is redefined to depend on the age (for controls) or age-of-onset (for cases), birth year, and sex. LT-FH++ incorporates family history and a population representative cumulative incidence proportions (CIPs), which makes it possible to account for censoring and stratification by sex and birth year in a liability threshold setup. Details on LT-FH and LT-FH++ are given in Section 3.3.

It is important to highlight that the family history methods have a clear advantage in that they can be used as a replacement for any phenotype in any further analysis. Going back to the example about Alzheimer’s disease, then the GWAX phenotype does not require any changes to the analysis plan. The only change is that the case-control status has been replaced by the GWAX phenotype. The same holds for the LT-FH phenotype, but with LT-FH there is no worry of any potential power loss, as it will always outperform GWAX and case-control phenotypes**todo:ref**. This is also true for LT-FH++ over LT-FH (and by extension GWAX)**todo:ref**. Since all of these refined family history phenotypes can be used as replacements for the original phenotypes, the methodological benefits can be used immediately and do not require further implementation or modification to make them compatible with the chosen GWAS software. For example, GWAS with a family history phenotype as the outcome can be performed with linear regression, or swapped to a linear mixed model with no other change. This means the family history methods builds on top of the methodological improvements that happen in parallel.

It is important to highlight that this is different from the survival GWAS methods that have been proposed, as they are all model specific implementations**todo:ref**. Each new model is not compatible with previous implementations. An example of this is SPACox and GATE. Both SPACox and GATE suffer from this drawback, as they invalidate any previously implemented

Cox PH or frailty method in a GWAS setting due to their applicability to large datasets. It also implies that any possible future model accounting for an aspect that available models do not account for at the present time, most likely will invalidate both SPACox and GATE, while LT-FH++ can be combined with future implementations immediately. LT-FH++ is therefore in a strong position, as it enables the user to immediately utilise new methodological advancements, while preserving the survival analysis aspect and its inherent power increase.

Many human traits are highly polygenic, which makes it difficult to identify the underlying mechanisms that causes the traits[24]. In particular, many psychiatric disorders have poorly understood biological mechanisms, are highly polygenic, and are very heritable[25, 26]. Because of this, polygenic traits such as psychiatric disorders often require larger sample sizes or better models compared to less polygenic traits[27–29]. Utilising additional information to assist in increasing statistical power for such phenotypes are therefore of particular interest, as it does not require additional individuals to be sequenced to increase power.

## Chapter 2

# Study Aims

The aims of the dissertation is to present an approach to account for both family history and time, as well as to improve the predictive value of family history in GWAS without increasing sample sizes. This was achieved by estimating a liability with a modified liability threshold model that depends on age-of-onset and family history. The thresholds used in the modified model are based on population representative cumulative incidence proportions stratified by sex and birth year. The following papers highlight different applications of the model.

### **Paper 1: LT-FH++**

The first paper is the flagship paper of the dissertation. During the development of this paper, most of the implementation work was done such that estimating the desired liability was possible. The work resulted in the method titled LT-FH++, which is an extension of the previously published method LT-FH. LT-FH++ allows one to estimate a liability for an individual based on information such as age or age-of-onset, sex, birth year, and family history. This additional information can also be accounted for in each of the family members included, which was not possible with LT-FH. We found that the additional information did improve power, however in some cases it is only a modest improvement, since most of the power gain is driven by family history.

### **Paper 2: ADuLT**

The second paper focused on the model underlying LT-FH++, called the age-dependent liability threshold (ADuLT) model, and its ability to increase power in GWAS compared to the more common Cox proportional hazards model. In this setting, the estimated liability depends on the same information as in the first paper, except we did not include family history and focused only on the age-of-onset aspect of the model. We only observed a notable difference between ADuLT and the CoxPH model when case ascertainment was present, but in such a case, the CoxPH was disproportionately affected and had a significantly lower power than ADuLT and even simple case-control linear regression.

### **Paper 3: fGRS**

**TODO:finish this**

## Chapter 3

# Materials and Methods

### 3.1 Data Sources

All projects in this dissertation are based on two types of information, register data and genotype data. The registers are used to define the study population, acquire phenotype information for individuals, and link family members. The genotype data is used to run a genome-wide association study (See Section 3.2 for details).

#### 3.1.1 Danish Registers

The Danish registers provide the main source of phenotypic information and allow us to link individuals to their family members. The registers can be linked to one another through a unique 10-digit number assigned to every Dane and resident in Denmark since 1968. In Figure 3.1 is a brief overview of which registers are used and how they are linked. Details on the mentioned registers will be provided in this section.

##### The Civil Registration System

The Danish Civil Registration System was established on the 2<sup>nd</sup> of April 1968, and all persons living in Denmark were registered for administrative use. All registered individuals were given a 10-digit unique personal identification number, commonly referred to as the CPR-number. The CPR-number is used to link individuals across all registers. This register holds information on gender, date of birth, place of birth, citizenship, identity of parents, and is continually updated with information on vital status, place of residence and spouses. On the 1<sup>st</sup> of May 1972 all persons living in Greenland were also included into this register[30].

##### The National Patient Register

The Danish National Patient Register was established in 1977. It has been expanded several times since it was created. Originally, it contained only information on patients admitted to somatic wards. In 1995, the register was expanded to also include outpatients, patients from emergency rooms, and patients from psychiatric wards. In 1994, the international classification of disease, version 10 (ICD-10) was adopted in Denmark, and prior to the adoption, ICD-8 was used[31].

## The Psychiatric Central Research Register

The psychiatric Central Research Register has valid data from 1970 and onwards. At the beginning, the register contained information on every admission to a mental hospital and psychiatric department, where information such as dates of onset, end of treatment, and all diagnosis were recorded. In 1995, the register became an integrated part of the Danish national patient register and was expanded to also record information from psychiatric emergency room and outpatient treatment. Similar to the national patient register, ICD-10 codes were used after 1995, and ICD-8 were used before. Note that most mild and moderate affected individuals are treated by general practitioners or in private practices, in which case they are not recorded in this register.[32]

## The Newborn Screening Biobank

The Danish Newborn Screening Biobank contains dried blood spot samples from nearly every newborn since 1982. The samples are taken from a heel prick a few days after birth and are stored at  $-20^{\circ}\text{C}$ . Each year about 65,000 new samples are added, resulting in over 1.8 million samples in 2007. The purpose of the biobank is, among other things, to screen for various diseases at birth. The samples are kept for research purposes, and the dried blood spots provide the basis for the iPSYCH cohort[33].




Figure 3.1: *Illustration of a selected number of Danish registers. They are linked together by the civil registration system. The year denotes the year the register starts.*

### 3.1.2 Cumulative Incidence Proportions

Another important aspect of the Danish registers is their usage in estimating population representative incidence proportions stratified by sex and year of birth. These CIPs are essential for estimating the thresholds used by LT-FH++, as they are used to account for age-of-onset. All CIPs used throughout our work were estimated by the aid of the Aalen-Johansen estimator with death and emigration as competing events[34, 76]. The Aalen-Johansen estimator of the survival function was used instead of the Kaplan-Meier estimator, as it accounts for competing events, i.e. different causes of censoring (death vs. independent censoring). As the Kaplan-Meier estimator estimates the overall survival function, it always overestimates the risk and can only approximate the true cumulative incidences in the presence of competing risks[35]. As the CIPs are stratified by sex and birth year, they can be interpreted as the proportion of individuals born in a specific year and of a given sex that are diagnosed with an underlying disorder prior to time point  $t$ . The data from the registers described above provide the basis for estimating these CIPs and an example of depression CIPs is provided in Figure 3.2. They are estimated for each birth year available in the Danish registers, but only shown for every fifth year. The red colour represents women's CIP and the blue is the men's CIP.



### 3.1.3 Genotype Data

This section covers the sources of genotype data used in this dissertation. There are two main sources, namely iPSYCH and UKBB. Here, we provide a brief overview for both of them. Notably, the iPSYCH cohort is a Danish biobank and has been linked to the previously mentioned registers, as shown in Figure 3.1.

#### iPSYCH




Figure 3.2: **Cumulative incidence proportions from the Danish Registers:** *Depression cumulative incidence proportions estimated from the Danish registers. The CIPs have been stratified by birth year and sex. The red colour represent women and the blue represent men. The CIPs are calculated for each birth year, but are only shown in steps of 5 years.*

and the child is alive and living in Denmark by their first birthday. iPSYCH2015i extended the study population to individuals born between 1<sup>st</sup> of May 1981 and 31<sup>st</sup> of December 2008 with the same conditions. In total, 1,657,449 individuals satisfy this condition. For the first round of sampling, 30,000 samples were chosen at random, creating a population representative control group. For iPSYCH2015i another 21,000 were sampled for the control group. From the study population, all individuals with at least one of the focus disorders were sampled for iPSYCH2015 resulting in 93,608 samples, and 50,615 population controls. However, due to the random sampling 385 were chosen as controls for both iPSYCH2012 and iPSYCH2015i and another 2,958

iPSYCH is a key source of genotype data used in this dissertation. The benefit of a biobank such as iPSYCH is not the number of genotypes, instead its strength is due to the richness of the register information that it is linked to. All of the previously mentioned Danish registers have been linked to the genotypes, allowing for a very detailed set of phenotypes, as well as multiple information on each individual and their family members. The iPSYCH cohort focuses on psychiatric disorders, namely Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, Anorexia Nervosa, Bipolar disorder, Depression, and Schizophrenia[36]. Ethical approval was given by the Danish Scientific Ethics Committee, the Danish Health Data Authority, the Danish data protection agency, and the Danish Neonatal Screening Biobank Steering Committee.

The iPSYCH cohort has been sampled in two rounds. The first round is called iPSYCH2012 and has 86,189 samples, while the second round, iPSYCH2015i, has 56,233 samples. The combined cohort is called iPSYCH2015 and has 141,265 unique samples. The population that iPSYCH2012 is nested within is defined as all singletons born in Denmark between the 1<sup>st</sup> of May 1981 and the 31<sup>st</sup> of December 2005, where the mother is known

individuals had at least one of the disorders iPSYCH focuses on, and would have been sampled either way[15, 36].

## UK Biobank

UK Biobank is the second main provider of the genotype data used in our studies. Since 2006, UKBB has evolved into one of the largest and most detailed, long-term biobank studies in the world, and its impact on the field of statistical genetics should not be underrated. As opposed to the Danish registers and iPSYCH, UKBB’s main advantage is its accessibility. It has open access, and it is possible for researchers from all over the world to gain access to the database by simply providing a summary of the research that is intended to be conducted, a description of any new data or variables that will be generated, and information on the UK Biobank data-fields that are required [13, 37].

As already mentioned, the UK Biobank is one of the largest of its kind, as it includes about 500,000 individuals. In addition, it has a large amount of environmental, lifestyle, and genetic data that is extended regularly. Among the information provided by the UKBB is genomic data of more than 800,000 genome-wide variants, electronic health-related records, and web-based questionnaires.

Since 2011, there has been questionnaires on diet, cognitive function, occupational history, mental health, digestive health, chronic pain, food preferences, mental well-being as well as health and well-being. Regarding genetic data, it is possible to access genotypes and imputed variants therefrom for 488,000 participants, whole-exome sequences for 470,000 participants and whole genome sequences for 200,000 participants (with more to follow)[13, 38, 39]. With respect to the electronic health-related records, primary care data is available for approximately 230,000 participants, hospital inpatient data is available for all participants. Death and cancer data is available due to the linkage to national death and cancer registries.

The phenotypic information linked to all UK Biobank participants is quite detailed. UKBB receives cancer registry data from the Information Centre and Information Service Division on a quarterly basis, and the records holds information on the data of cancer diagnosis, the participant’s age at cancer diagnosis, the ICD-10 and ICD-9 codes for the type of cancer, the reported occurrences of cancer, the histology code as well as the behaviour code [40].

In addition, UKBB receives death registry data from NHS Digital and the NHS Central Register every six month at the latest. The death records are similar to the cancer registry data and hold information on the date of death, the ICD-10 code for the primary cause of death, the ICD-10 code for the secondary cause of death, as well as the origin and format of the death record. Up until 2019, some of the death records also contain free-text cause of death information from the death certificate describing the sequence leading to death[41].

However, one prevailing disadvantage of the UK Biobank is the lack of registered family history. The available data regarding family members was obtained through touchscreen questionnaires and include only information on parents and siblings that the participants were able (or willing) to share. More precisely, the data contains information about the illnesses of the adopted or biological father, mother, and siblings, as well as the number of adopted or full brothers and sisters. Even more restrictive is the number of diseases that have been considered in these questionnaires, which is only 12. Participants were asked whether their adopted or biological parents and siblings had been diagnosed with severe depression, Parkinson’s disease, Alzheimer’s disease (dementia), diabetes, high blood pressure, chronic bronchitis (emphysema), breast, bowel, prostate or lung cancer, stroke, or heart disease. This number is low compared to the total number of registered phenotypes, which is several thousands.

Even if family history is not commonly used in statistical genetics at the present time, it

has been included in analyses performed within epidemiology and other fields for many years[7, 8, 10, 42]. Recently, some methods accounting for family history, such as GWAX and LT-FH, have been proposed, highlighting the necessity to include high quality health records for family members in biobanks.

## 3.2 Genome-Wide Association Study

This section will briefly go over what a genome-wide association study (GWAS) is, some common considerations, and models used. First, we will present some commonly used model, then cover important topic for performing a GWAS, namely controlling type 1 errors, computational efficiency, and power improvement. At the end, we will also provide a non-exhaustive list of methodological advancements that excel in one or more of these topics.

### 3.2.1 Common GWAS Models

A GWAS is usually performed on a single SNP at a time, rather than all SNPs at the same time, meaning effect sizes are marginal instead of joint. There are several potential models that can be used to analyse genotypes, and in the early days of GWAS the Cochran-Armitage test [43, 44] was used [45]. It has since been superseded by linear regression models, and in recent days there have been a push towards linear mixed models. These models will be presented here.

#### Cochran-Armitage

The Cochran-Armitage test tests for independence in a  $2 \times 3$  contingency table. However, this test is not able to incorporate covariates to account for important covariates such as population stratification (See Section 3.2.2 for details). Therefore, regression based methods become popular, as they allow for covariates to be included. If a GWAS is performed with a regression, it implicitly assumed that the genetic effect from a given SNP will be additive, which is not the case for a Cochran-Armitage test. The implicit assumption follows from how the genetic data is coded for regression as  $AA = 0$ ,  $Aa = 1$ , and  $aa = 2$ , where  $A$  is the major allele and  $a$  is the minor allele[46]. When restricting to only additive genetic effects, there is no difference between linear regression and the Cochran-Armitage test[47]. Since a Cochran-Armitage based GWAS is not able to incorporate covariates, it is no longer commonly used.

#### Linear Regression GWAS

A simple and computationally efficient way to test association between a SNP and an outcome, even when the outcome is binary, is with linear regression. If we have  $N$  individuals for whom we observe a set of  $M$  SNPs, then a linear regression GWAS of a single SNP can be described in the following way.

Let  $y$  denote the  $N \times 1$  vector of phenotypes for each individual, either binary or quantitative,  $X$  be the  $N \times (k + 1)$  matrix containing  $k$  covariates and the intercept (a column of 1s),  $G_j$  is a  $N \times 1$  vector containing the  $j^{th}$  SNP, then the model is given by:

$$y = \beta G_j + X\gamma + \varepsilon, \quad (3.1)$$

where  $\beta$  denotes the genetic effect size,  $\gamma$  denotes a  $(k + 1) \times 1$  vector of coefficients for the intercept and covariates,  $\varepsilon$  is a  $N \times 1$  vector of independent normally distributed noise. Going forward, we will assume without loss of generality that both  $y$  and  $G_j$  are scaled to have mean 0 and variance 1. The hypothesis being tested is  $H_0 : \beta = 0$  against  $H_A : \beta \neq 0$ .

In short, regression methods are preferred over the Cochran-Armitage test as covariates can be included and linear regression is sometimes preferred over logistic regression, since it is more computationally efficient and there is no discernable difference between their power[45, 47–49]. Although logistic regression is more suitable when the outcome is binary, the linear regression p-values approximate the logistic-regression p-values well in practice, except when the outcome is rare or when the estimated effect is large (see Section 3.2.2)[50].

### Linear Mixed Model GWAS

A linear mixed model is an extension of a linear regression model. The linear mixed model adds a random effect to the model given in Equation (3.1). With all other parameters being the same, we get

$$y = \beta G_j + X\gamma + Zu + \varepsilon \quad u \sim N(\mathbf{0}, \Sigma) \quad (3.2)$$

The random term  $u$  and the noise  $\varepsilon$  are independent. Here  $Zu$  has an interpretation similar to  $X\gamma$ , as  $Z$  is a design matrix for  $u$ , but one that helps model the covariance structure. Then  $u$  is a random vector, and we can define the covariance structure of  $u$  by  $\Sigma$ . In a GWAS setting, the covariance structure that one would like to model is some subset of SNPs. It can be achieved by letting  $Z = Z' / \sqrt{M}$ , where  $Z'$  denotes the matrix with the desired subset of SNPs. Therefore,  $\Sigma$  will be a genomic relationship matrix (GRM) calculated based on a preselected subset of SNPs. If we let  $K = ZZ^T$  denote the GRM on the subset of SNPs, we can express the covariance of the vector  $y$  in the following way

$$\text{cov}(y) = \sigma_g^2 K + \sigma_e^2 I_N. \quad (3.3)$$

Where  $\sigma_e^2$  is the environmental variance component,  $I_N$  is the  $N \times N$  dimensional identity matrix,  $\sigma_g^2$  is the genetic variance component, and  $K$  is the GRM on a subset of SNPs. With the choice of  $I_N$  for the environmental covariance structure, an independent environment is implicitly assumed for all individuals. Similarly,  $K$  allows individuals with a high correlation to be accounted for. The mixed model requires estimates of  $\sigma_e^2$  and  $\sigma_g^2$ . Computationally, linear mixed models are far more intensive than linear regression, but the benefit of these models is their ability to boost power over simple linear regression[4]. See Section 3.2.5 for details on computational and mathematical tricks that can speed up the computations.

### Proportional Hazards Model GWAS

A proportional hazards model is commonly used to model the *time to an event* for various outcomes. It models the changes in the hazard function, which can be thought of as the instantaneous chance of experiencing the event at some point in time,  $t$ . The model used for GWAS is given by

$$\lambda(t|X, G_j) = \lambda_0(t) \exp(X\gamma + \beta G_j) \quad (3.4)$$

where  $\lambda_0(t)$  is the baseline hazard,  $X$  denotes the covariates,  $\gamma$  is the covariate effects,  $G_j$  is the genotype, and  $\beta$  is the SNP effect. We note that a baseline hazard affects everyone, and the model can then examine the influence of covariates and the SNP in comparison to the baseline. The association test of interest is  $H_0 : \beta = 0$  vs  $H_A : \beta \neq 0$ . The baseline hazard is rarely known, but a common way to perform an association test in a proportional hazards model is with a likelihood ratio test, where the unknown baseline cancel out. A partial likelihood function is commonly used, which only maximises with respect to the variable of interest, here  $\beta$ .

### 3.2.2 Controlling Type-1 and Type-2 Errors

Controlling type-1 and type-2 errors is extremely important in a GWAS setting, as the same tests will be performed millions of times across the genotypes. Common causes of type-1 errors (also called a false positive) and type-2 errors (also called false negatives) are population structure, multiple testing correction, and unbalanced case-control phenotypes. These terms cover several types of potential problems in a GWAS setting. If the problems are not accounted for they can result in spurious associations between SNPs and phenotypes or mask true associations. The most common reasons for population structure in genotype data is due to *population stratification* and *related individuals*. Multiple testing correction is a fundamental problem in statistics that we will briefly introduce one solution for. Unbalanced case-control phenotypes can have many causes, such as low prevalence of a disorder or biases in recruitment.

#### Population Stratification




Figure 3.3: Scatter plot of the first two principal components of iPSYCH participants coloured by parental country of birth: The plot is provided without modification from the original paper describing the population structure in iPSYCH [36]. The first two principal components have been plotted for the iPSYCH participants and coloured according to the parent's country of birth. The large circles indicate the mean values of a given genetic ancestry group. The circles with a cross represent the individuals where both parents are born in the region indicated by the colour, and no cross means only one parent was.

Population stratification is an umbrella term, and it can have many causes. We will consider two types of population stratification, namely local subpopulations in an otherwise homogeneous population and different genetic ancestries.

Within a population of individuals, it has been shown that there can be subpopulations where allele frequencies differ between subpopulations [51, 52]. It can cause artificial differences or similarities between the subpopulations when performing associations tests. One example of a spurious association driven by population stratification is the chopstick gene, which allegedly accounted for half of the variance in being able to eat with chopsticks [53, 54]. A common and simple solution to account for local population stratification is to perform a principal component analysis (PCA) on the genotypes and including the first

principal components (PCs) as covariates in the association analysis [55–57]. Local population stratification can also be accounted for by modelling the covariance structure of a select subset of SNPs in a linear mixed model GWAS.

The above solution works well if only local subpopulations are present in an otherwise homogeneous population. A problem may arise if there are two or more genetic ancestries, as the PCs may not be able to properly account for such stratification. As a result, it seems prudent to highlight this particular cause of population stratification. Analysing different ancestries together in a GWAS is not commonly done. This is because different ancestries may have different minor allele frequencies for certain SNPs, altogether different variants on certain positions, etc.[58]. Therefore, the most common way to deal with different genetic ancestries in a genotyped data set is to identify a genetically homogeneous subset and perform the association analysis in the homogeneous subpopulation. There have been methods proposed that can account for genetic ancestry such as Tractor[59], but they have not been widely adopted yet.

A homogeneous subpopulation can be identified by performing a PCA on all the available individuals and calculating a robust Mahalanobis distance on the first, e.g. 20 PCs, and removing anyone above a certain threshold[57]. An illustration of the feasibility of identifying the genetic ancestry for the iPSYCH participants can be seen in Figure 3.3.

## Relatedness

Similar to population stratification, relatedness is a common cause of spurious associations in GWASs. However, the mechanism behind why relatedness leads to these spurious associations is a little different. If related individuals are in the same analysis, then some individuals are more alike than one would expect if they were drawn at random. Due to this, deviations from the null distribution are likely to occur, not due to the SNP's effect, but rather the sampling. For a Wald test deviation could be expressed as a downwardly biased variance estimate, which leads to inflated test statistics, as the test statistics is the effect estimate divided by the standard error [60–62].

There are two common ways to deal with relatedness in a GWAS setting. The first and simplest way is to identify the related individuals and removing them from the analysis. This is effective, but has the downside of reducing the sample size. The second and more involved way is to include the in-sample relatedness (sometimes also called cryptic relatedness) in the model being used for association. In a linear regression setting, the most common way to account for the cryptic relatedness is by using a linear mixed model, where a random effect that models the genotype correlation is added (see Section 3.2.1 for details). The random effect is able to account for the covariance structure of the individuals, which is how relatedness affects associations with higher than expected correlations[63, 64]. The cryptic relatedness is accounted for by having the covariance structure of the random effect follow the GRM.

If one decides to remove the related individuals instead, then there are several ways to identify the related individuals, with the two most common ways being the GRM and identity-by-descent [65–68]. The GRM consists of the correlation between individual's genotypes, where a value of 1 corresponds to monozygotic twins or duplicate samples, 0.5 to a parent-offspring or sibling relationship, etc.. An identity-by-descent approach for identifying relatedness is provided by the KING software[68], and a GRM based approach is provided by the GCTA software [65]. Both ways of estimating relatedness is also implemented in the PLINK software[66, 67]

## Multiple Testing Correction

A GWAS consists of testing each available SNP for an association with the phenotype of interest. This means several million tests are often performed. A classic statistical approach to hypothesis testing means a test has a significance threshold denoted by  $\alpha$ , which is most commonly 0.05 (or 5%). If the p-value is below  $\alpha$ , the null hypothesis is rejected and the alternative hypothesis is accepted. Due to the p-values being uniformly distributed under the null hypothesis, we will

expect to have  $(100 \times \alpha)\%$  of the tests performed rejects the null hypothesis purely by chance. There are ways to account for this. The most common multiple testing correction method used in GWAS is the Bonferroni correction[45, 69]. As a motivation for the Bonferroni correction, let  $n$  independent tests be given, then the family-wide error rate  $\bar{\alpha}$ , meaning the probability of seeing at least one false positive across all  $n$  tests, is given by

$$\bar{\alpha} = 1 - (1 - \alpha)^n \quad (3.5)$$

$\alpha$  is the per-test significance level. This leads to the Bonferroni correction  $\alpha_{bf} = \alpha/n$ . By comparing the repeated tests against  $\alpha_{bf}$  instead of  $\alpha$ , the expected number of false positives will remain  $\alpha$  across all tests performed, thereby controlling the number of type-1 errors. In a GWAS setting, it is common to assume 1 million independent tests are performed[70], which leads to a genome-wide significance threshold of  $5 \times 10^{-8}$ .

### Unbalanced Case-Control Phenotypes

If a case-control phenotype is used in a GWAS, where the case-control ratio exceeds 1:80, it may have significantly inflated test statistics[71]. Ma et al.[72] frames the same problem in terms of minor allele count (MAC) and suggests a MAC of 400 or higher for a well-balanced test. The unbalanced case-control phenotypes lead to inflated test statistics because the tests often rely on asymptotic distribution assumptions. These assumptions do not seem to hold if the MAC is low or if the case-control ratio is unbalanced. While BOLT-LMM provided an efficient implementation for linear mixed models, further study of the software has revealed that it suffers from inflated test statistics[73].

Methods such as SAIGE[71], SPACox[20], GATE[21], and REGENIE[73] have been proposed to combat the inflation of test statistics due to deviations from the asymptotic distribution assumptions. A strategy most of these methods utilise is the saddle point approximation (SPA)[74, 75]. One of the advantages of using SPA is that it provides good control of Type 1 error, even for unbalanced case-control phenotypes and as such do not suffer from inflation of the test statistic in such cases[73].

SPA can efficiently estimate cumulative distribution function (CDF) probabilities from only the cumulant generating function,  $K$ . Let  $T$  be the test statistics of a commonly used GWAS association test statistics, then the CDF of  $T$ , which is needed to calculate p-values, is approximated by

$$\mathbb{P}(T < x) = \Phi(w + w^{-1} \log(v/w)) \quad (3.6)$$

with  $\Phi$  denotes the standard normal CDF and

$$w = \text{sign}(\hat{\zeta}) \left[ 2 \left( \hat{\zeta}x - K(\hat{\zeta}) \right) \right]^{1/2}, \quad v = \hat{\zeta} \sqrt{K''(\hat{\zeta})} \quad (3.7)$$

where  $\hat{\zeta} = \hat{\zeta}(x)$  is the solution to  $K'(\hat{\zeta}) = x$ , with  $K'$  and  $K''$  denoting the first and second derivative of the cumulant generating function. If the test statistic is close to the mean, a normal approximation is usually good. As a result, the normal distribution is often used if the test statistic is within two standard deviations of the mean, and the SPA otherwise.

### 3.2.3 Censoring

Censoring is an important concept to consider, especially when analysing time-to-event phenotypes. Focus is usually on the time to disorder onset, but conceptually it is also important to

be able to account for individuals not experiencing the disorder being analysed, but still going through a period of being at-risk. This is the purpose of censoring. If a study is performed and a period of time is considered for a population, then not everyone is expected to experience the disorder. It is in fact very common that a large group of participants will not experience any disorder onset, but they have still lived through a period of being at-risk. Censoring of information is then allowing some individuals to not be fully observed or observable. There can be numerous reasons for why this may happen. For example, if a sample population is followed for a period of time, then some participants may leave the study for unrelated causes. Those causes may be death, moving away such that participation is no longer possible, or no longer satisfying the inclusion criteria for the study.

Censoring can be grouped into different categories and we will consider three types here. If a survival analysis is performed, then some individuals may have already experienced the disorder of interest prior to the beginning of the study. This is referred to as left-censoring, as the event happened prior to observations and it is sometimes not known when. If an individual in a study is observed for a period of time, but is unavailable for some time, and an event happens in this unobserved period of time, that is called interval-censoring. The participants may be unavailable because they move away for a period of time, and then come back and resume participation in the study. The last type of censoring that will be considered here is right-censoring. It is similar to left-censoring, but instead of the event happening before the study period, it happens after [76]. An illustration of censoring types is presented in Figure 3.4.




Figure 3.4: : Illustration of left, interval, and right censoring in time-to-event data.

If an age-of-onset analysis is performed in a GWAS setting, it is usually done with a Cox PH model (see Section 3.2.1 for details). However, these models are not as widespread as variations of



linear or logistic regression for GWAS. This means most GWAS does not account for, e.g. right-censoring, which can be very common for some phenotypes. As an example, late-onset disorders such as Alzheimer’s disease or some types of heart diseases are likely to suffer from censoring in most GWAS analysis, because participants will not have lived long enough to experience these. In this dissertation, we will present a method, LT-FH++, that is able to account for censoring, while also accounting for family history at the same time (see Section 3.3 for details).

### 3.2.4 Bias

Bias is an important concept to consider when performing a statistical analysis. There are many different types of biases that can influence an analysis, such as immortal time bias, attrition bias, collider bias, and confounding. A catalogue of potential biases has been compiled[77]. Each of these biases have the potential to significantly influence statistical analysis if it is not properly identified and accounted for. Even though there are many biases to consider, this section we will primarily highlight ascertainment bias, as it is prevalent in a GWAS setting.

Ascertainment bias can be briefly summarised as a systematic difference between the case-control ratio in the entire population and the sampled population. In practical terms, ascertainment means there will be either fewer or more cases in the sampled population compared to the whole population. This can be a significant problem if important subgroups are systematically missing or overrepresented in the sampled population, as spurious associations may arise or mask true associations. The effect of under or over representation of cases (case ascertainment) on the liability distribution in a sampled population is shown in Figure 3.5. If the cases are undersampled, it may be difficult to identify the true associations, as observed differences may be variations in the control group. With oversampling, the over representation of cases may result in inflated differences between the cases and controls. Therefore, it is important to be able to account for such sampling situations. A common way of accounting for case ascertainment is with inverse probability weights (IPW) [78]. IPW consists of weighing each observation with the inverse of the probability of the observation being sampled. It is commonly used in epidemiology, but to a lesser extend in a GWAS setting[79].

### 3.2.5 Computational Efficiency

This section will cover some of the common computational or mathematical tricks used to speed up GWAS. Biobanks have been steadily increasing in size. it is therefore more important than ever to have as efficient methods as possible, since we would otherwise risk having data sets too large to properly analyse. We will briefly describe how one can avoid estimating the effect sizes of covariates that have been included in the model and tricks on how to avoid inverting matrices.

#### Projecting Covariates

There is a computational cost involved in estimating the effects of the covariates. Therefore, the most efficient way to account for the covariates without directly calculating their effect in each regression is to project them out of the predictor and the response of interest in Equation (3.1) [48]. For the sake of completeness, we will present how to regress out the covariates as they were presented by Sikorska et al.[48].

Considering the residual sum of squares(RSS) for Equation (3.1), we get

$$RSS = (y - \beta G_j - X\gamma)^T (y - \beta G_j - X\gamma) \quad (3.8)$$

$$= y^T y - 2\beta y^T G_j - 2y^T X\gamma - \beta^2 G_j^T G_j + 2\beta G_j^T X + \gamma^T X^T X\gamma. \quad (3.9)$$




Figure 3.5: : The effect of case ascertainment in the liability threshold model, where the cases are either under- or oversampled.

Recall that  $X\gamma$  is a vector of dimension  $N \times 1$ , which means  $y^T X\gamma$  is an inner product and inner products are symmetric. Differentiating the residual sum of squares with respect to  $\beta$  and  $\gamma$  yields

$$\frac{\partial}{\partial \beta}(RSS) = -2y^T G + 2\beta G_j^T G_j + 2G_j^T X\gamma \quad (3.10)$$

$$\frac{\partial}{\partial \gamma}(RSS) = -2y^T X + 2\beta G_j^T X + 2X^T X\gamma \quad (3.11)$$

Setting these expressions equal to 0, we get

$$G_j^T G_j \beta + G_j^T X\gamma = G_j^T y \quad (3.12)$$

$$X^T G_j \beta + X^T X\gamma = X^T y \quad (3.13)$$

This means the matrix notation of the least squares solution to Equation (3.1) is given by

$$\begin{pmatrix} G_j^T G_j & G_j^T X \\ X^T G_j & X^T X \end{pmatrix} \begin{pmatrix} \hat{\beta} \\ \hat{\gamma} \end{pmatrix} = \begin{pmatrix} G_j^T y \\ X^T y \end{pmatrix}. \quad (3.14)$$

and we will let  $\hat{\beta}$  and  $\hat{\gamma}$  denote solutions to the least squares equations. However, we are interested in an expression that does not depend on the covariates. From here we isolate  $\hat{\gamma}$  in Equation (3.13) and get  $\hat{\gamma} = (X^T X)^{-1}(X^T y - \hat{\beta} X^T G_j)$ , which is then inserted in to Equation (3.12)

$$G_j^T y = G_j^T G_j \beta + G_j^T X (X^T X)^{-1} (X^T y - \hat{\beta} X^T G_j). \quad (3.15)$$

By isolating terms related to  $y$  on the left hand side and term related to  $\hat{\beta}$  on the right hand side we get the following

$$G_j^T(y - X(X^T X)^{-1} X^T y) = G_j^T(G_j - X(X^T X)^{-1} X^T G_j) \hat{\beta}. \quad (3.16)$$

Recall that  $X(X^T X)^{-1} X^T$  denotes the projection onto the space spanned by the matrix  $X$ . From here, we will introduce transformations given by

$$y^* = y - X(X^T X)^{-1} X^T y \quad G_j^* = G_j - X(X^T X)^{-1} X^T G_j. \quad (3.17)$$

The transformations remove the effect of the covariates in  $X$  from the response and predictor of interest. Using the properties of projections, Equation (3.16), and the transformations, we find that

$$(G_j^*)^T G_j^* \hat{\beta} = G_j^T G_j^* \hat{\beta} \stackrel{3.16}{=} G_j^T y^* = (G_j^*)^T y^*. \quad (3.18)$$

The normal equation for systems of equations of the form  $Ax = b$  say that  $\hat{\beta}$  is a solution to a new univariate regression given by

$$y^* = \hat{\beta} G_j^* + \varepsilon \quad \text{with simplified solution} \quad \hat{\beta} = \frac{(G_j^*)^T y^*}{(G_j^*)^T G_j^*}. \quad (3.19)$$

With the projection, the effect of the covariates have been removed from the outcome and the predictor, i.e. the phenotype and the genotype do *not* depend on  $\gamma$  any more. Therefore, the calculations have been simplified and the calculations for the projection matrix only has to be performed once. Accounting for the covariate's effect in the phenotype also only has to be done once, the removal of the covariate's effect on the SNP has to be done for each SNP separately.

### Avoiding Large Matrix Inversions

In this section, we will focus on ways of improving the computational efficiency of linear mixed models. First, a short introduction to which calculations are the most computationally intensive will be provided. Secondly, a way to circumvent the direct calculations will be provided. We will use the mixed model implementation in BOLT-LMM as an example.

BOLT-LMM utilises a stochastic restricted maximum likelihood (REML) approach to estimate the variance components from Equation (3.2). The approach is called stochastic, since it utilises Monte Carlo sampling. The estimate acquired is a REML estimate, as all covariates have already been projected out of the phenotype vector,  $y$ , the genotypes,  $G_j$ , and the environment,  $\varepsilon$ . This means degrees of freedom been reduced by  $C$ , which is the rank of the design matrix  $X$ . On top of this, all observations will now belong to an  $N - C$  dimensional subspace of  $\mathbb{R}^N$ , and the distribution of the environmental term is now changed to  $\varepsilon \sim N(\mathbf{0}, \sigma_e^2 P)$ , where  $P$  denotes the projection matrix on the space spanned by  $X$ . Recall that a projection is symmetric and idempotent, hence only  $P$  is left in the covariance matrix of  $\varepsilon$ .

In this reduced setup, we will present how the variance components are estimated in an efficient manner under the infinitesimal model. First, we will reframe the problem in terms of a Bayesian setting where all of the covariates have been projected out. In the notation of Equation (3.2), we have

$$y = Z\beta + \varepsilon, \quad \text{cov}(y) = \sigma_g^2 K + \sigma_e^2 P \quad (3.20)$$

where each SNP's effect has the prior  $\beta_j \sim N(0, \sigma_j^2)$  with  $\sigma_j^2 = \sigma_g^2/M$ . The *stochastic* REML then simulates observations under the model in Equation (3.20) and attempts to find a solution

to an equivalent problem. With a slight abuse of notation of  $\|\varepsilon\|^2$  and  $\|\beta\|^2$ , we can phrase the alternative problem that we will solve as

$$E \left[ \sum \hat{\varepsilon}_{rand}^2 \right] = \sum \hat{\varepsilon}_{data}^2, \quad E \left[ \sum \hat{\beta}_{rand}^2 \right] = \sum \hat{\beta}_{data}^2. \quad (3.21)$$

Here  $\hat{\beta}_{data}^2$  and  $\hat{\varepsilon}_{data}^2$  are the best linear unbiased prediction (BLUP) estimates in Equation (3.20). The terms in the expectation are  $\hat{\beta}_{rand}^2$  and  $\hat{\varepsilon}_{rand}^2$  and they are simulated values under the same model, but with a known and fixed  $\sigma_g^2$  and  $\sigma_e^2$ . The simulated values are given by

$$y_{rand} = Z\beta_{rand} + \varepsilon_{rand}, \quad \beta_{rand,j} \sim N(0, \sigma_j^2), \quad \varepsilon_{rand,j} \sim N(0, \sigma_e^2). \quad (3.22)$$

Hence, the left hand side of Equation (3.21) can be estimated by samples generated from Equation (3.22) with fixed and known variance components and the right hand side can be estimated with a BLUP estimator. This setup allows for iteratively calculating the BLUP estimates and estimating the variance components. We will outline how this iterative scheme is performed now. First, we will assume that we have  $\sigma_g^2$  and  $\sigma_e^2$  known and fixed. Then, we will define the following

$$\delta := \frac{\sigma_e^2}{\sigma_g^2}, \quad H := K + \delta I_N. \quad (3.23)$$

From here, the BLUP estimates are given by

$$\hat{\beta} = \frac{1}{M} Z^T H^{-1} y, \quad \hat{e} = \delta H^{-1} y \quad (3.24)$$

Note that the BLUP estimates are constant for a fixed  $\delta$ . With this, we can calculate the BLUP estimates. Next, we need a way to find estimates of the variance components,  $\sigma_g^2$  and  $\sigma_e^2$ . We will rephrase Equation (3.21) as a single equation that depends on  $\delta$  with

$$\frac{E \left[ \sum \hat{\beta}_{rand}^2 \right]}{E \left[ \sum \hat{\varepsilon}_{rand}^2 \right]} = \frac{\sum \hat{\beta}_{data}^2}{\sum \hat{\varepsilon}_{data}^2}. \quad (3.25)$$

where we can scale  $\sigma_g^2$  such that it matches the observed data. From here, we can get 1 on the left hand side of the rephrase equation above, and take the logarithm on both sides to get

$$f_{reml}(\log(\delta)) := \log \left( \frac{E \left[ \sum \hat{\varepsilon}_{rand}^2 \right] \sum \hat{\beta}_{data}^2}{\sum \hat{\varepsilon}_{data}^2 E \left[ \sum \hat{\beta}_{rand}^2 \right]} \right). \quad (3.26)$$

As a result, we have to find a value of  $\delta$  which satisfy  $f_{reml}(\log(\delta)) = 0$ . We will not elaborate on the details of how this is done, but it involves using the secant method and a sampling strategy similar to the one used above for the BLUP estimate. In summary, estimating the variance components in a mixed model, as presented in BOLT-LMM, means calculating the BLUP estimates in Equation (3.24) and finding  $\delta$  that solves Equation (3.26). However, the calculations needed to perform the iterative scheme require inverting a matrix. Matrix inversion is computationally expensive and has computational complexity of  $O(N^3)$  if calculated naively. Other strategies have been suggested, which allows for a computational complexity of  $O(NM^2)$  or  $O(N^2M)$  [80, 81]. The strategy employed in BOLT-LMM has a computational complexity of  $O(NM)$ , which makes it much faster.

The variance of the phenotype, as seen in Equation (3.3) or in the iterative scheme as Equation (3.24) will have to be inverted, if calculated naively. We can efficiently perform calculations

of the form  $H^{-1}y$  and circumvent the inversion by finding solutions to  $Hx = y$ , as the solution will be equivalent to  $\hat{x} = H^{-1}y$ . As we are looking for solutions to the system of equations given by  $Hx = y$ , we can multiply with some vector,  $x$ , from the right. The only computationally expensive terms that make up  $H$  is only the GRM term,  $ZZ^T/M$ , as  $\delta I_N$  is easy to calculate. However, we can express it in the following way

$$ZZ^T x = \sum_i (Z_i Z_i^T) x = \sum_i Z_i (Z_i^T x) \quad (3.27)$$

The first equation expresses  $ZZ^T$  as the sum of the outer products of columns of  $Z$  and the second as a sum of vectors times a scalar, where the scalar is the result of an inner product between the  $i^{th}$  column of  $Z$  and the given vector  $x$ . This reformation of the product  $ZZ^T x$  has computational complexity  $O(NM)$ .

### 3.2.6 Increasing Power in GWAS

Increasing power to detect true associations has been another primary focus of GWAS method developments. The leap from linear regression to a linear mixed model is expected to provide a power increase [4]. The increase comes from modelling the covariance structure present in the data, which is not possible for linear regression. As the covariance structure is modelled, it is no longer necessary to remove individuals due to relatedness or population stratification. This has the additional benefit that the sample size increases, which in turn increases power.

Another source of power improvement is accounting for the effect of other SNPs. When one accounts for other SNPs in this manner, it essentially means a reduction in the residual variance of the phenotype, which is also why it has been referred to as *denoising* the phenotype[82]. Reducing the residual variance of the phenotype has proven to be an effective way to increase power in a GWAS, and we will briefly present how it can be done. Again, we will use BOLT-LMM as an example.

BOLT-LMM utilises an infinitesimal model and a Bayesian model with mixture Gaussian priors. This mixture model allows for a non-infinitesimal model to be used, as some SNPs will be set to 0 and the variance for groups of SNPs can vary. In a linear mixed model setup, as seen in Section 3.2.1 and with the covariance of  $y$  given as  $V = \sigma_g^2 G^T G / M + \sigma_e^2 I_N$ , the test statistic is given by

$$\chi_{LMM}^2 = \frac{(G_j^T V^{-1} y)^2}{G_j^T V^{-1} G_j} \quad (3.28)$$

with  $\sigma_g^2$  and  $\sigma_e^2$  estimates under the null hypothesis  $H_0: \beta = 0$ . However, performing a test in this way means accounting for the same SNPs more than once, as the SNP of interest will also be present in the GRM. We can avoid it by removing the chromosome that the  $j^{th}$  SNP belongs to from the GRM calculations. This is called leave-one-chromosome-out (LOCO). We will denote the LOCO GRM as  $V_{LOCO} = (G_{LOCO})^T G_{LOCO} / M_{LOCO}$ , where  $G_{LOCO}$  is the SNP that remain after removing the  $j^{th}$  SNP's chromosome and  $M_{LOCO}$  is the number of SNPs after removing the same chromosome. We get the LOCO test statistic to be

$$\chi_{LOCO}^2 = \frac{(G_j^T V_{LOCO}^{-1} y)^2}{G_j^T V_{LOCO}^{-1} G_j} \quad (3.29)$$

Notably, this means calculating a  $V_{LOCO}$  for each chromosome. The BOLT-LMM infinitesimal model has a test statistic that is given by

$$\chi_{BOLT-INF}^2 = \frac{(G_j^T V_{LOCO}^{-1} y)^2}{c_{inf}} \quad c_{inf} = \frac{\text{mean}((G_j^T V_{LOCO}^{-1} y)^2)}{\text{mean}(\chi_{LOCO}^2)} \quad (3.30)$$

Where  $c_{inf}$  is chosen such that  $\text{mean}(\chi_{BOLT-INF}^2) = \text{mean}(\chi_{LOCO}^2)$ . The constant  $c_{inf}$  is estimated from 30 pseudo-random SNPs. As we are able to account for some of the other SNPs with the LOCO testing scheme in BOLT-LMM, we achieve a power increase.

When introducing the Gaussian mixture prior, they generalise the test statistic as

$$\chi_{BOLT-LMM}^2 = \frac{(G_j^T y_{residual})^2}{c} \quad (3.31)$$

where  $y_{residual}$  is a residual phenotype vector obtained after fitting a Gaussian mixture extension of the standard LMM. The model used to fit the phenotype is still using LOCO, but to ease notation, the notation has been suppressed. The calibration factor  $c$  is chosen such that the intercept of  $\chi_{BOLT-LMM}^2$  with LD score regression[83] model matches the intercept of the properly calibrated  $\chi_{BOLT-INF}^2$ .

The test statistic for the non-infinitesimal model require calculating the residualised phenotype  $y_{residual}$ . Next we will describe how those are obtained. Under a Bayesian framework, the null model associated with Equation (3.29) is given as

$$y = G_{LOCO} \beta_{LOCO} + \varepsilon \quad \beta_j \sim N(0, \sigma_g^2 / M_{LOCO}), \quad \varepsilon \sim N(\mathbf{0}, \sigma_e^2 I_N) \quad (3.32)$$

Note that the model is infinitesimal as all SNPs  $\beta_j$  follow the same distribution. The generalisation to a Gaussian mixture prior means replacing the prior for  $\beta_j$  with

$$\beta_j \sim \begin{cases} N(0, \sigma_{g1}^2) & \text{with probability } p \\ N(0, \sigma_{g2}^2) & \text{with probability } 1 - p \end{cases} \quad (3.33)$$

This prior is sometimes called a spike-and-slab prior, since one of the variances  $\sigma_{g1}^2$  or  $\sigma_{g2}^2$  may be very large while the other may be very small. This results in two normal distributions, one very concentrated around 0, and another that allows for large variations in effect sizes. If illustrated, this looks like a spike around 0, and a slab covering a large area, hence the name.

The effect sizes,  $\beta_j$ , are estimated from Equation (3.32), and the residualised phenotype under the Gaussian mixture prior vector is calculated as

$$y_{residual} = y - G_{LOCO} \beta_{LOCO} \quad (3.34)$$

The residualised phenotype vector,  $y_{residual}$ , is then used in Equation (3.31). In summary, using the infinitesimal model with the LOCO scheme, increases power compared to simple linear regression. Using the mixture prior, increases the effective sample size by an additional 25% compared to the infinitesimal model [4].

### 3.2.7 Notable Methodological Advancements

This section provides a non-exhaustive list of methodological advances proposed for GWAS. The list aims to highlight key advances that have been made by either providing computational feasibility for a certain type of analysis, use of a more complex model, or both. Notable GWAS methods are presented in Table 3.1.

Software	Notable advancement	Model
PLINK[66, 67]	Highly scalable linear and logistic regression & Data management and standardised a binary storage format	Linear & logistic regression
BOLT[4]	Efficient linear mixed model for UKBB sized data that accounts for cryptic relatedness & increases power	Linear mixed model
SPACox[20]	Saddle point approximation based proportional hazards model for UKBB sized data	Cox proportional hazards
GATE[21]	Saddle point approximation based frailty model for UKBB sized data	Frailty model

Table 3.1: *Overview of notable GWAS methods*

### 3.3 Liability Threshold Model, Family History & Age-of-Onset

This section deals with how to utilise family history and age-of-onset to increase power in a GWAS. All published methods that account for family history redefine or recalculate the phenotype. This type of improvement is different from the main focus for methodological developments so far, with methods such as BOLT-LMM[4], REGENIE[73], and GATE[21] that account for cryptic relatedness in the genotypes. The research into accounting for family history by refining the phenotype has been very limited in comparison. This is likely due to the relatively low occurrence of family history information in conjunction with genotype data. There have been some biobanks, such as UK biobank[13], deCODE[14], iPSYCH[15, 36], and FinnGen[16], where some level of family history information have been linked with genotypes.

The first method we will introduce that accounts for family history is genome-wide association study by proxy (GWAX)[17]. GWAX is not a model based approach, but rather a heuristic way to account for family history. Next, we will present the liability threshold model originally introduced by Falconer[22] and extensions of this model. We will present two extensions, the first is called liability threshold model conditional on family history (LT-FH)[18] and the second is called LT-FH++. LT-FH++ has been developed and implemented during this PhD. As a result, it is the method this dissertation is focused on. LT-FH++ is an extension of the LT-FH method that is also able to account for age-of-onset or age, sex, and cohort effects in each included individual, while being very computationally efficient.

#### 3.3.1 GWAX

The first method that accounts for family history information is called GWAX. The method was developed and applied for Alzheimer’s disease in UK biobank[17]. It managed to increase power for a phenotype that had a low prevalence in the UK biobank participants, but was present and had a higher prevalence among their parents due to the late age-of-onset of Alzheimer’s disease. GWAX is a heuristic method, i.e. not set in a statistical model, and the method only utilises family history and no age- or sex-related information. The GWAX phenotype is a binary variable. It considers close relatives as well when assigning case status, instead of only assigning case status based on the UK biobank participant themselves. This means an individual without

Alzheimer’s disease, but with a parent who did have Alzheimer’s disease would be considered a case under GWAX. This approach is simple and easy to use, acts as a drop-in replacement for any previous binary phenotype, and achieved the desired result of increasing power in a GWAS setting. In short, GWAX was a big success and a proof of concept for other family history methods. There have been model based developments in family history methods since GWAX was published. The family history methods are based on the LTM, and we will therefore present it and explain how it was expanded.

### 3.3.2 The Liability Threshold Model

The LTM is widely used to explain how binary phenotypes can have complex aetiologies and do not behave as a Mendelian disease. Under the liability threshold model an individual will have a latent variable (a liability),  $\ell \sim N(0, 1)$ . The case-control status  $z$  for a given phenotype is given by

$$z = \begin{cases} 1 & \ell \geq T \\ 0 & \text{otherwise} \end{cases},$$

i.e. an individual is a case when the liability  $\ell$  is above a given threshold  $T$  and the threshold is determined by the prevalence  $k$ , such that  $\mathbb{P}(\ell > T) = k$  in the population. An illustration of the LTM is provided in Figure 3.6.

The LTM allows for modelling of non-Mendelian diseases, since the latent liability can be the result of more complex mechanisms than Mendelian diseases, which may depend on more than one or two genes [22, 23].

### 3.3.3 LT-FH

The extension proposed by Hujoel et al.[18] is called LT-FH. It allows for a dependency between the genetic liability of the family members and the index person. There is no theoretical limitation on the family members to include in the model, however the original implementation only allows for both parents, the number of siblings, and a binary variable of whether any sibling has the phenotype being analysed. This is unfortunately a limitation of the data available to the authors when LT-FH was developed. In UKBB, sibling information is limited and it is only coded as present or not in any of the siblings, so we do not know which sibling(s) are affected.

#### The Model

The first part of the extension is to split the full liability  $\ell_o$  in a genetic component  $\ell_g \sim N(0, h^2)$ , where  $h^2$  denotes the heritability of the phenotype on the liability scale, and an environmental component  $\ell_e \sim N(0, 1 - h^2)$ . Then,  $\ell_o = \ell_g + \ell_e \sim N(0, 1)$  and the genetic and environmental




Figure 3.6: *Illustration of the classical liability threshold model. Liabilities above the threshold  $T$ , correspond to a case diagnosis, while liabilities below  $T$  are controls.*



components are independent. Others have also proposed this split into genetic and environmental components, however not with family history as well [84]. The second extension is to consider a multivariate normal distribution instead of a univariate one. For illustrative purposes, we will only show the model for which both parents are present, but no siblings.

$$\ell = (\ell_g, \ell_o, \ell_{p_1}, \ell_{p_2}) \sim N(\mathbf{0}, \Sigma)^T \quad \Sigma = \begin{bmatrix} h^2 & h^2 & 0.5h^2 & 0.5h^2 \\ h^2 & h^2 & 0.5h^2 & 0.5h^2 \\ 0.5h^2 & 0.5h^2 & 1 & 0 \\ 0.5h^2 & 0.5h^2 & 0 & 1 \end{bmatrix} \quad (3.35)$$

LT-FH does not distinguish between mother and father and the parents are coded as  $p_1$  and  $p_2$ . If available, siblings can be included in the model as well by extending the dimension of the multivariate normal distribution with the number of siblings to include. Siblings would also have a variance of 1 and a covariance of  $0.5h^2$  with the other family members, reflecting the liability scale heritability of the phenotype and the expected genetic overlap. If siblings are included and one is a case, then the genetic liability will be estimated under the assumption of *at least one sibling is a case*. Meaning, the genetic liability is estimated for one case, two cases, etc. among the siblings, and the final estimate is a weighted average of these genetic liabilities.

### Input

With this framework, the expected genetic liability can be estimated given the family member's case-control status. Estimating the expected genetic liability  $\hat{\ell}_g$  means estimating

$$\hat{\ell}_g = \mathbb{E}[\ell_g | \mathbf{Z}] \quad \mathbf{Z} = (z_o, z_{p_1}, z_{p_2})^T$$

where  $\mathbf{Z}$  is the vector of the considered family member's case-control status. The condition on  $\mathbf{Z}$  in the LTM means the liabilities for each family member is restricted to an interval. For a case, the full liability would be restricted to  $(T, \infty)$ , while the full liability of a control would be restricted to  $(-\infty, T)$ . If we let  $i$  indicate a given family member, e.g.  $o, p_1, p_2$  and  $n$  denotes the size of the family under consideration, then the possible liabilities for a family of all cases can be described as  $\{\ell \in \mathbb{R}^n | \ell_i \geq T_i \text{ for all } i\}$ . If instead a family of all controls was considered, it would be  $\{\ell \in \mathbb{R}^n | \ell_i < T_i \text{ for all } i\}$ . The genetic liability of the index person is always unrestricted. Commonly, the area of interest would be some combination of the two sets. The restrictions on the liabilities leads to a truncated multivariate normal distribution, and calculating the expected genetic liability  $\hat{\ell}_g$  does not have an analytical solution. See **Sampling Strategy** for details on how LT-FH estimates the genetic liabilities.

A practical consideration for LT-FH is the choice of thresholds. LT-FH considers two thresholds, one for the parents,  $T_p$ , and one for the children,  $T_c$ . The thresholds should reflect the prevalence for these groups, and a common strategy is to use the in-sample prevalences from UKBB. The in-sample prevalences work well enough for LT-FH in UKBB for a few reasons. First, the UKBB has a large sample size. Second, it has not been sampled for any specific phenotypes (even though they are healthier than the general population). Lastly, the LT-FH model is very robust to misspecification of its parameters.

### Sampling Strategy

The sampling strategy used in the original implementation of LT-FH consists in sampling a large number of observations from the multivariate normal distribution, then splitting the samples into

each of the possible configurations of  $\mathbf{Z}$ , and calculate the  $\hat{\ell}_g$  by averaging within each group. More observations are sampled if the standard error of mean (sem) is larger than 0.1 in any of the configurations of  $\mathbf{Z}$ . If we consider only the index person, then we will have only 2 configurations to estimate the genetic liability in and it will essentially be a rescaled case-control phenotype. If we consider the index person and one parent, we will have 4 configurations, and with two parents, there are 6 configurations, since the sex of the parent is not considered. Once siblings are considered, the max number of siblings will be considered as well as status. For up to 10 siblings and no parents, there will be 40 unique configurations. From here it scales by counting the number of siblings present, if any siblings are cases, and the parental status. A pseudocode overview of the sampling strategy can be found in Algorithm 1.

If a given configuration does not have an estimate of  $\hat{\ell}_g$  with  $\text{sem}(\hat{\ell}_g) < 0.1$ , some resampling will be performed. This resampling is slightly more targeted than the initial sampling. For illustrative purposes, consider resampling from the configuration where one or two parents are a case, i.e.  $z_{p1} = 1$  and/or  $z_{p2} = 1$ , then univariate samples will be drawn from a truncated normal distribution on  $(T_p, \infty)$  for a case and  $(-\infty, T_p)$  for a control. Then the full model given in Equation (3.35) is conditioned on the targeted parental liabilities and the mean and covariance matrix in a conditional normal distribution are calculated and denoted by  $\mu^*$  and  $\Sigma^*$ , respectively. Notably, not all observations from the lower dimensional conditional normal distribution are guaranteed to be observations for the desired configuration. The resampling strategy is applied until  $\hat{\ell}_g$  has a sem below 0.1 in all configurations.

---

**Algorithm 1 :** LT-FH sampling strategy

---

**Input:**  $h^2, n_{sib}, \mathbf{Z}, T_p, T_c$

**Output:**  $\hat{\ell}_g$  for all configurations

```

1: sample  $\ell \sim N(\mathbf{0}, \Sigma)$ 
2: split into disjoint sets from  $\mathbf{Z}$ 
3: calculate  $\hat{\ell}_g$  in each configuration
4: while  $\text{sem}(\hat{\ell}_g) \geq 0.1$  for any configuration do
5:   if  $z_{p1} = 1$  or  $z_{p2} = 1$  then
6:     sample  $\ell \mid (z_{p1}, z_{p2})^T \sim N_{n-2}(\mu^*, \Sigma^*)$ 
7:   else if  $z_o = 1$  or  $z_s \neq \mathbf{0}$  then
8:     sample  $\ell \mid (z_o, z_s)^T \sim N_{n-(n_{sib}-1)}(\mu^*, \Sigma^*)$ 
9:   end if
10:  update  $\hat{\ell}_g$ 
11: end while
```

---

### 3.3.4 LT-FH++

The model underlying LT-FH and LT-FH++ is fundamentally the same, however LT-FH++ does make a few modifications to account for age-of-onset or, sex, and cohort effects. The addition of this extra information allows for a more fine-tuned estimate of the genetic liability  $\hat{\ell}_g$ , further improving the genetic liability estimates. The modifications that allow for the additional information has an impact on the input and choice of sampling strategy. Therefore, this section will primarily focus on how these key points differ from LT-FH, since the fundamental model is the same, it will not be repeated.




Figure 3.7: **Age-dependent liability threshold model and its relationship to the CIPs:** An illustration of how the population representative CIPs are used by the age-dependent liability threshold model. The CIPs are stratified by sex and birth year (here ADHD for individuals born in Denmark in 2000) are converted to a threshold for the ADuLT model. Females are represented by the red line, while males are represented by the blue line. The CIPs has been marked at the age of 10 and 15 for both sexes (dotted lines).

### The Model

The model underlying LT-FH++ is very similar to LT-FH and does not differ in a major way from what is shown in eq. 3.35. The model used by LT-FH++ deviates from the one used in LT-FH in the family members that can be accounted for, and what information is used for each family member. In short, LT-FH considers the index person and siblings the same, since the same threshold,  $T_c$ , is used for each of the children in LT-FH, and the parents are also treated the same and share the threshold  $T_p$ . LT-FH++ allows for each individual to have their own personalised threshold  $T_i$ , for all  $i$  in the family. The individual thresholds are based on population representative cumulative incidence proportions (CIPs). The CIPs have the interpretation of "being the proportion of individuals born in year  $y$  that have experienced a phenotype before age  $t$ ". We let  $s_i$  denote the sex of individual  $i$ , which means  $k(t; s_i, b_i)$  is the CIP for individual  $i$ 's sex born in year  $b_i$  at time  $t$ .

$$\mathbb{P}(\ell_i > T_i) = k(t; s_i, b_i) \Rightarrow T_i = \Phi^{-1}(1 - k(t; s_i, b_i)),$$

where  $\Phi$  denotes the CDF of the standard normal distribution. An individual's current age for control or age-of-onset for cases, their sex, and birth year will be accounted for through the choice of threshold and denoted by  $T_i$ . The threshold are determined through the CIPs, which means the thresholds are also a function of  $t$ , but unless it is an important distinction to make that notation will be suppressed. See Section 3.1.2 for details on the CIPs. If the CIPs are stratified by birth year and sex, a more accurate estimate of an individual's full liability is provided. When age-of-onset is available for a case, their full liability can be fixed to  $T_i$ , rather than spanning the interval  $(T_i, \infty)$ . Furthermore, for controls the threshold will decrease as the population ages,

which narrows the potential liabilities, since they have lived through a period of risk. This means that older controls will have a lower estimated liability. An illustration of how the personalised thresholds can be used in the ADuLT model see Figure 3.7.

## Input

The input for LT-FH++ is similar to the input for LT-FH, but with two notable differences. The first difference is that LT-FH++ relies on CIPs for the threshold for each individual, while LT-FH utilises a general but separate threshold for parents and offspring. The second notable difference is that each family member will have to be included separately, while LT-FH does not distinguish between mother and father and only requires the total number of siblings and whether any siblings are cases. An overview of LT-FH++ and the information it is able to account for is provided in Figure 3.8. The sex and birth year stratified CIPs are used to assign thresholds to each individual in a family. Each person will

therefore have a lower  $T_i^l$  and upper  $T_i^u$  threshold, which leads to an interval of possible liabilities defined as  $I_i = (T_i^l, T_i^u)$ . For controls, the interval will be  $I_i = (T_i^l, T_i^u) = (-\infty, T_i)$ , while for cases  $I_i = (T_i^l, T_i^u) = [T_i, T_i]$ . If a user does not have CIPs that are stratified by sex and birth year, then a case's interval should be given as  $I_i = (T_i, \infty)$ . When the thresholds have been assigned, the intervals that the truncated multivariate normal distribution have been defined and the genetic liability can be estimated.

## Sampling Strategy

Due to the unlikeliness that two families will consist of the exact same sex, age-of-onset, etc., and fixing the upper and lower limit for cases, the truncated normal distributions will be unique to each family. The straight-forward sampling approach employed by LT-FH is therefore not computationally tractable any more. Instead LT-FH++ employs a Gibbs sampler to sample directly from a truncated multivariate normal distribution with predefined limits. To further improve the computational complexity of LT-FH++, we have used a slightly modified version of the Gibbs sampler approach suggested by the *tmvtnorm* R package[85, 86]. Pseudo code of the Gibbs sampler used by LT-FH++ is presented in Algorithm 2.

**Step 1: Estimate posterior genetic liability for each individual using Gibbs sampling**

$$\hat{l}_g = E \left( l_g \mid \begin{array}{c} \text{Case-control status} \\ \text{for genotyped} \\ \text{individual} \end{array} ; \begin{array}{c} \text{Gender} \end{array} ; \begin{array}{c} \text{Age} \end{array} ; \begin{array}{c} \text{Birth year} \end{array} ; \begin{array}{c} \text{Population} \\ \text{prevalence by age,} \\ \text{sex, and birth year} \end{array} \right)$$

**Step 2: Perform GWAS with estimated genetic liability as outcome**

$$\hat{l}_g = x_j \beta_j + \dots$$

Predicted genetic liability      Effect of the  $j^{\text{th}}$  genetic variant      Additional covariates, PCs, sex, age, random effects, etc.

**Figure 3.8: Overview of LT-FH++ and what information it can account for in GWAS:** *This plot is taken as-is from the original LT-FH++ paper[19]. Using LT-FH++ is a two step approach. First, a genetic liability is estimated based on the available family history, where age-of-onset or age for controls, sex, and birth year is accounted for in each included individual. Then a GWAS can be performed with the GWAS software of choice, e.g. BOLT-LMM.*

---

**Algorithm 2** : LT-FH++ sampling strategy

---

**Input:**  $h^2$ ,  $T_i^l$ ,  $T_i^u$  and each family member's role

**Output:**  $\hat{\ell}_g$  for all index persons

**Gibbs Sampler:**

```
1: Initialise  $\ell^{(0)}$  as  $\mathbf{0}$  and pre-compute  $\Sigma_{12}\Sigma_{22}^{-1}$  and  $\Sigma_{12}\Sigma_{22}^{-1}\Sigma_{21}$  for  $\mu_i^{(s)}$  and  $\sigma_i^2$ 
2: for  $s = 1, \dots, S$  do
3:   for  $j = 1, \dots, n+1$  do // n+1 is family size + genetic liability
4:      $U \sim \text{Unif}(I_i) = \text{Unif}(T_i^l, T_i^u)$  // Ensures truncation
5:      $\ell_j^{(s)} = F_{N(\mu_i^{(s)}, \sigma_i^2)}^{-1}(U)$ 
6:   end for
7: end for
8: if  $\text{sem}(\hat{\ell}_g) \geq 0.1$  then
9:   rerun Gibbs Sampler
10: else
11:   return  $\hat{\ell}_g$ 
12: end if
```

---

### 3.3.5 LT-FH++ with Correlated Traits

LT-FH++ can be extended to include correlated traits. Many disorder pairs have a non-zero genetic correlation, which is often not used. There exist methods that can account for correlated traits, with the most popular method being MTAG[87]. However, MTAG requires a GWAS to be run on each of the correlated phenotypes and can then account for some of the genetic signal between the phenotype's summary statistics. Both MTAG and LT-FH++ can account for multiple correlated phenotypes at a time. LT-FH++ deals with correlated traits by using the additional traits to further refine the liability estimate of the primary phenotype, while MTAG uses summary statistics to correct for each other's effect. This means a single GWAS is performed with a LT-FH++ phenotype that accounts for case-control status and family history of the correlated phenotype(s), rather than separate GWASs being run for each phenotype.

If two phenotypes are genetically correlated, the LT-FH++ model can account for the correlated phenotype by extending the covariance matrix. The simplest way to account for correlated phenotypes requires the same information as a single trait analysis, so stratified CIPs and family history for each phenotype, as well as the genetic correlation of the considered phenotypes. The thresholds will be determined within each phenotype with the disorder specific CIPs.

If we consider  $\ell_1$  and  $\ell_2$  as the vectors of liabilities for some family for two genetically correlated disorders, each of the vectors can be modelled as seen above for a single trait. However, the interaction between the two disorders would be ignored. Setting  $h_1^2$  and  $h_2^2$  to be the liability-scale heritability for the two disorders and setting  $\Sigma^{(1)}$  and  $\Sigma^{(2)}$  to be the covariance matrices for the two genetically correlated disorders, we can model the interaction with the following model

$$\ell = (\ell_1, \ell_2)^T \sim N(\mathbf{0}, \Sigma), \quad \Sigma = \begin{pmatrix} \Sigma^{(1)} & \Sigma^{(12)} \\ \Sigma^{(21)} & \Sigma^{(2)} \end{pmatrix}, \quad \Sigma_{ij}^{(12)} = K_{ij}\rho_{12}\sqrt{h_1^2 h_2^2},$$

where  $\Sigma_{ij}^{(12)}$  is the expected genetic overlap between two individuals and genetic covariance between the disorders, expressed by the genetic correlation  $\rho_{12}$  and the heritabilities. We can generalise the construction of the covariance matrix such that it can be used to create the between-disorder covariance as well as the with-in disorder covariance matrix for the considered family. First, let  $K_{ij}$  denote the expected genetic overlap between individuals  $i$  and  $j$ , let  $\rho_{nm}$

be the genetic correlation between phenotype  $n$  and  $m$ . If we only consider one phenotype, then  $\rho_{nn} = 1$ . Then we can construct the covariance matrix entry-wise with

$$\Sigma_{ij}^{(nm)} = K_{ij}\rho_{nm}\sqrt{h_n^2 h_m^2}, \quad K_{ij} = \begin{cases} 1 & \text{if } i \text{ and } j \text{ the same} \\ 0.5 & \text{if } i \text{ and } j \text{ 1}^{st} \text{ degree} \\ 0.25 & \text{if } i \text{ and } j \text{ 2}^{nd} \text{ degree} \\ 0.125 & \text{if } i \text{ and } j \text{ 3}^{rd} \text{ degree} \\ 0 & \text{otherwise} \end{cases}$$

With this construction, it is also possible to readily extend the considered family members to a broader pedigree. The considered pedigrees in the LT-FH and the LT-FH++ papers only allowed for first degree relatives. This limitation has been loosened, and far broader pedigrees can now be used. The extensions to the possible family members were made while developing the correlated trait implementation. The correlated trait and extended family were intended to be used in the fGRS paper **TODO: proper reference**. The extended family means we can account for family history in children of the index person, paternal and maternal grandparents, half-siblings, aunts, and uncles can also be considered. Considering the extended family and correlated traits both serve the purpose of further refining the liability estimate.

There are not changes to the sampling strategy, as the Gibbs sampler proposed is scalable to many dimensions.

### 3.3.6 LT-FH++ and Survival Analysis

The proportional hazards model is defined by the hazard function. The connection to a hazard function is not clear under a liability threshold model. However, a rate can be considered the probability of an event happening in an infinitesimally small change in time. Under the LTM, the hazard rate can therefore be interpreted as the probability of an individual being diagnosed in such an infinitesimally small change in time[88]. To describe such a probability, we will let  $T(t)$  be the threshold for an individual to be a case at time  $t$ ,  $\ell$  is a person's full liability, and  $x$  denotes the covariates, e.g. genotypes and sex. The approximation is given by the following conditional probability

$$\lambda(t|x) \approx \mathbb{P}(T(t+dt) < \ell \mid T(t) > \ell, x) / dt. \quad (3.36)$$

Here  $dt$  denotes a small change in time. This means the hazard rate is proportional to the probability of an event occurring in a time interval  $(t, t+dt)$  given no event has occurred before time  $t$ .

Under the age-dependent liability threshold model, we can derive the probability of becoming a case in an interval  $(t, t+dt)$  shown in Equation (3.36). Recall that the threshold  $T(t)$  used to determine case status is monotonic decreasing with age, as the cumulative incidence proportion for a given sex and birth year is monotonic increasing with age. The ADuLT model assumes that an individual's full liability is given by the genetic and environmental components,  $\ell_i = g_i + e_i$ . Notably,  $g_i$  and  $e_i$  are independent, normally distributed with variances  $h^2$  and  $1 - h^2$ , respectively. By using properties of conditional probabilities, we get

$$\mathbb{P}(T(t+dt) \leq \ell_i | T(t) > \ell_i, g_i) \quad (3.37)$$

$$= \mathbb{P}(T(t+dt) \leq \ell_i < T(t) | g_i) \times \mathbb{P}(T(t) > \ell_i | g_i)^{-1} \quad (3.38)$$

$$= \left[ \Phi \left( \frac{T(t) - g_i}{\sqrt{1 - h^2}} \right) - \Phi \left( \frac{T(t+dt) - g_i}{\sqrt{1 - h^2}} \right) \right] \times \Phi \left( \frac{T(t) - g_i}{\sqrt{1 - h^2}} \right)^{-1} \quad (3.39)$$

$$= 1 - \Phi \left( \frac{T(t+dt) - g_i}{\sqrt{1 - h^2}} \right) \times \Phi \left( \frac{T(t) - g_i}{\sqrt{1 - h^2}} \right)^{-1}. \quad (3.40)$$

With Equation (3.40) note the fraction will always be less than 1 due to the monotonic decreasing property of the threshold. Furthermore, if we consider an individual  $i$ , where  $t_i$  denote the current age or age-of-onset, then we can calculate the survival function under the ADuLT model. Recall that if  $t_i$  is larger than the currently considered point in time,  $t$ , no event has occurred, and is equivalent to a liability under the threshold. We get

$$S_i(t) = \mathbb{P}(t_i > t) = \mathbb{P}(\ell_i < T_i(t)) = \Phi \left( \frac{T_i(t) - g_i}{\sqrt{1 - h^2}} \right). \quad (3.41)$$

From the survival function, we can determine the hazard function with a well known formula

$$\lambda_i(t) = \frac{-S'_i(t)}{S_i(t)}. \quad (3.42)$$

The model is unusual compared to other survival models in the particular way that it is unique to each individual, as the genetic component and threshold all depend on the individual. Older individuals will have a lower threshold and individuals with a high genetic risk are more likely to become cases. The thresholds,  $T_i$ , do not have to approach negative infinity as the population increases. In fact, the thresholds will have a lower limit that correspond to the life-time prevalence in the population. Put in another way, the thresholds are stopping times that has the halting criteria of being diagnosed or dying.

At a first glance, the ADuLT model may seem deterministic and therefore be incompatible with survival analysis. However, it is important to note that an individual's liabilities are never observed, which means the environment component can be thought of as capturing environmental effects, chance events, and other non-genetic effects. This leads to a model that is non-deterministic, thereby preserving the stochastic nature of survival models.

# Chapter 4

## Results

This section will summarise the results of the scientific papers the dissertation is based on. All papers utilised some version of the LT-FH++, which will be referred to as age-dependent liability threshold model when no family history is being used. Each paper has its own distinct use case of the model, which will be highlighted in the coming sections.

### 4.1 Paper 1 - LT-FH++


The first paper proposed the method LT-FH++, which is an extension of the previously proposed LT-FH method by Hujoel et al[18]. The most notable difference between LT-FH and LT-FH++ is the ability to account for age-of-onset for cases or age for controls, sex, and birth year, as well as the same information in the included family members. The LT-FH method does not consider sex or age in parents, meaning they have the same thresholds. It also uses the same threshold for the index person and siblings and does not distinguish on age or sex differences. LT-FH++ is also able to account for siblings individually rather than considering the number of siblings and an “at least one affected sibling” indicator. This way of coding siblings in LT-FH is likely due to the way sibling information is coded in the UKBB, which was the main application of the LT-FH paper. Considerable changes have also been made to the sampling strategy to allow for the increased flexibility in the family and the use of personalised thresholds to be scalable to millions of individuals. The changes LT-FH++ proposed increased the number of unique configurations considerably, as each individual now has a unique set of family members and thresholds. The sampling strategy used for LT-FH would be computationally intractable for LT-FH++, since LT-FH only needed to estimate a liability for a handful of configurations.

#### 4.1.1 Simulation Results

We performed simulations to assess the power and false discovery rate of LT-FH++ against LT-FH and a case-control status to detect causal SNPs in a linear regression GWAS. The simulations are based on simulated genotypes, where we simulated a pair of parents and one offspring with no siblings. We used parameters similar to the ones used in the LT-FH paper to ensure compatibility between findings. The simulated genotypes had a heritability on the liability scale of  $h^2 = 0.5$ , a population prevalence of 5%. Unlike in the LT-FH paper, we used a higher prevalence in one of the simulated sexes, but the combined prevalence would still be 5%. The case ratio was 1:4 between sexes, and it was also present in the parents. We also considered a population prevalence of 10%, but those results are not shown here. The genotypes consisted of 100,000



individuals, each with 100,000 independent SNPs where 1000 SNPs were causal, i.e. they had a simulated effect size different from 0. The simulation results shown in Figure 4.1 are based on 10 replications of each simulation scenario. Case ascertainment is common in biobanks, which means there is a higher (or lower) prevalence of a phenotype of interest in the biobank compared to the rest of the population (See Section 3.2.4 for details). We emulated case ascertainment in the simulations by downsampling the entire population until we had a subpopulation with 10,000 individuals with the same number of cases and controls.



**Figure 4.1: Simulation results for a 5% prevalence, with and without downsampling of controls:** Linear regression was used to perform the GWAS for LT-FH and LT-FH++, while a 1-df chi-squared test was used for case-control status. We assessed the power of each method by considering the fraction of causal SNPs with a  $p$ -value below  $5 \times 10^{-8}$ . Here, GWAS refers to case-control status and LT-FH and LT-FH++ are both without siblings. Downsampling refers to downsampling the controls such that we have the same number of cases and controls, i.e. we have 10,000 individuals in total for a 5% prevalence and 20,000 individuals for a 10% prevalence.

The simulations show a modest power increase in favour of LT-FH++ over LT-FH in the full sample, with an average power increase across the 10 simulations of 4%. Both LT-FH and LT-FH++ has an average power increase of more than 50% compared to the case-control status used in GWAS, making either method vastly better. However, case ascertainment has a significant impact on the power ratio between LT-FH and LT-FH++. When case ascertainment is present in a biobank, the average power increase of LT-FH++ over LT-FH increased to 18%.

### 4.1.2 Real-World Analysis

LT-FH++ was also applied to four of the main psychiatric disorders in iPSYCH and to mortality in UKBB. The mortality GWAS in UKBB resulted in 0 genome-wide significant SNP for simple linear regression, 2 for LT-FH, and 10 for LT-FH++. The Manhattan plot for mortality can be found in Figure 4.2.

The GWAS in iPSYCH did not provide nearly as large of an increase in power for LT-FH++ or LT-FH over simple linear regression. In fact, we did not see any notable improvement over simple linear regression of the case-control status. The Manhattan plot for ADHD in iPSYCH can be found in Figure 4.3. We did find 7 genome-wide significant SNPs for ADHD using LT-FH++ and 5 for LT-FH and case-control status, but the two additional associations for LT-FH++ were very close to genome-wide significance for the other two outcomes as well. Through additional simulations we found that one can expect the most *relative* power gain with LT-FH++ over LT-FH if the in-sample prevalence is high in either family members or the index persons. This is because LT-FH++ is best able to utilise information for cases, since the CIPs provide a very accurate estimate for the full liability of an individual.




Figure 4.2: **Manhattan plots for LT-FH++, LT-FH, and case-control GWAS of mortality in the UK Biobank:** The Manhattan plots display a Bonferroni corrected significance level of  $5 \times 10^{-8}$  and a suggestive threshold of  $5 \times 10^{-6}$ . The genome-wide significant SNPs are coloured in red. The diamonds correspond to top SNPs in a window of size 300,000 base pairs.

## 4.2 Paper 2 - ADuLT

The second paper utilised the ADuLT model, which is the model underlying LT-FH++. The name change is in large part due to the focus on only the age-dependency and not family history, even though it is the same model. The purpose of the project was to examine the performance of the ADuLT outcome with established time-to-event GWAS methods that are based on the Cox proportional hazards (PH) model. It is two fundamentally different ways to approach time-to-event analysis in a GWAS setting. The adoption of Cox PH models in a GWAS setting has been limited, which has also been evident in the relative lack of method developments for Cox PH models compared to other regression models. Since one of the main limitations for Cox PH is the computational cost of such a model, GWAS with these models have been limited to less than 100,000 individuals. Recently, a method called SPACox [20] has been proposed that allows for far better scaling, and allowing for analysis of large biobanks. We will use SPACox as a representative of Cox PH models to compare to in this paper.




Figure 4.3: **Manhattan plots for LT-FH++, LT-FH, and case-control GWAS of ADHD in the iPSYCH data:** The dashed line indicates a suggestive  $p$ -value of  $5 \times 10^{-6}$  and the fully drawn line at  $5 \times 10^{-8}$  indicates genome-wide significance threshold. The genome-wide significant SNPs are coloured in red. The diamonds correspond to top SNPs in a window of size 300,000 base pairs.

### 4.2.1 Simulation Results

As for the first paper, we assessed the models in simulations first. We simulated the genotypes and assigned phenotypes with two generative models. The first model was the liability threshold

model and the second model was the proportional hazards model. Notably, one would expect a method based on the liability threshold model to perform the best under this model, and subpar under other generative models. The simulation results shown in Figure 4.4 show the power for 10 replications under two different generative models and for different population prevalences. In Figure 4.4A, the ADuLT or case-control status methods perform slightly better than the Cox PH model under the liability threshold model and vice versa, which is what we expected. Notably, there is no case ascertainment in those simulations. The results shown in Figure 4.4B are with case ascertainment and we observe a large shift in power between methods under both generative models. In short, the simulation results show that the Cox PH based method has a far lower power than the LTM based methods under both generative models, when cases are ascertained. Even after performing inverse probability weighing Cox PH on a select subset of null SNPs and all causal SNPs, we observed the same result. This indicates that the Cox PH models with the current implementation suffers from a significant power loss when case ascertainment is present in a GWAS setting, which is very common in practice.




Figure 4.4: **Power simulation results with 250 causal SNPs under both generative models and varying prevalences.:** The power is shown for different population prevalence, varying from 1% to 20%. **A)** The power, i.e. the fraction of causal SNPs detected for each method, **without downsampling**. **B)** The power **with downsampling**, i.e. the number of individuals is subsampled to 10,000 cases and 10,000 controls.

### 4.2.2 Real-World Analysis

Next, we applied the same analysis to real-world data to assess whether we observed the same behaviour with case ascertainment present in the data. iPSYCH is particularly useful for this, as all cases in a given time period have been sampled and sequenced, meaning the iPSYCH data has a high case ascertainment.

We found that the Cox PH model had a rather large loss of power compared to ADuLT and case-control status. Across the four analysed psychiatric disorders, ADuLT found 20 independent associations, case-control status found 17, and SPACox found 8. The ADHD Manhattan plots for the three methods compared in paper 2 can be found in Figure 4.5. In no circumstances did the Cox PH model outperform a LTM based method, showing that the currently implementation of Cox PH model does not perform as well as simpler models such as linear regression, which are also far more computationally efficient.




Figure 4.5: **Manhattan plots from GWAS with the ADuLT phenotype, SPACox, and case-control status for ADHD:** Manhattan plots for ADHD for all three methods. Case-control GWAS uses the age of individuals as a covariate, whereas the ADuLT GWAS and SPACox do not. The orange dots indicate suggestive SNPs with a p-value threshold of  $5 \times 10^{-6}$ . The red dots correspond to genome-wide significant SNPs with a p-value threshold of  $5 \times 10^{-8}$ . The diamonds correspond to the lowest p-value LD clumped SNP in a 500,000 base pair window with an  $r^2 = 0.1$  threshold.

## 4.3 Paper 3 - fGRS

The final paper does not focus on GWAS, but rather on the predictive value of the LT-FH++ phenotype as an alternative to the conventional binary family history variable in prediction models. In epidemiology, family history is a well-known and powerful predictor that has been used to improve prediction models of complex phenotypes such as mental disorders, suicide, and heart disease [8, 89, 90]. As the intension is to provide an estimate of an individual's liability for a given disorder before getting an actual diagnosis, we will not consider the case-control status of the index person, but only the family members. In many ways this is similar to the purpose of PRSs and how it is currently being used to screen individuals for disorders. However, instead of using the individual's genotypes to acquire an aggregate genetic risk score, we will use the family history to estimate a liability.

### 4.3.1 Real-World Analysis

We will consider a base model that contains the index person's sex, age, and 20 PCs. We will add additional predictors to the base model and assess the additional predictive value of each predictor. We will use the partial  $R^2$  as a measure of predictive value. From the additional predictors and combinations of them, we can derive the best family history variable and the best overall model. We will consider the PRS for a given disorder, as well as a binary family history indicator or the LT-FH++ phenotype, but with the index person's status removed. We present the results in Figure 4.6. We calculated the average partial  $R^2$  across 8 phenotypes available to iPSYCH, but we left out eating disorders, as there were almost no family history available. We find that the LT-FH++ phenotype provided a 19.6% increase over the the PRS model, while the binary family history variable had a predictive value 65.2% lower than the PRS model. Of the models with only two predictors, the best model was the one with the PRS and LT-FH++ phenotype predictors. They had an average partial  $R^2$  of 111% across the 8 disorders, resulting in a partial  $R^2$  value that is close the sum of each predictor. The model with both family history variables had almost the same predictive value as the model with only the LT-FH++ variable, indicating that most of the predictive value is captured by the LT-FH++ phenotype. The same is also true for the model where both family history variables and the PRS is included. It is very close to the predictive value of the model with only the LT-FH++ phenotype and the PRS.

### Multi-Trait Prediction

On top of this, we will also considered correlated phenotypes. Mental disorders are notoriously difficult to diagnose and many mental disorders have a high genetic correlation [91, 92]. Accounting for correlated phenotypes is therefore an attempt at utilising the information from the highly correlated phenotypes to improve prediction. For correlated trait, we restricted to the iPSYCH disorders. This was done due to the requirement of genetic correlations, which has already been calculated by Schork et al.[91]. In order to have as fair of a comparison as possible, we also created multi trait models for the other predictors. For instance, we considered a multi trait PRS model, which is a model with the PRS of all the considered correlated phenotypes. Similarly, the binary family history variable for all the correlated phenotypes was also included. For LT-FH++, we considered two scenarios. The first is the correlated phenotype extension as presented in Section 3.3.5. It resulted in a single liability estimate that represents the family history for all of the considered disorders. We also considered a simpler approach, where the single trait LT-FH++ phenotype was included for each of the considered phenotypes. The first approach for LT-FH++ did not perform as well as the other methods, and will not be pre-




Figure 4.6: **Average out-of-sample prediction across 8 disorders:** Average partial  $R^2$  across 8 disorders with various prediction models. We excluded eating disorders from the average, as hardly any family history was present for these disorders. The base model includes age, sex, and 20 PCs. PRS refers to the base model with the PRS included as well. FH refers to the base model with the binary family history, and FL refers to the LT-FH++ variable. Combinations of these variables are presented as PRS & FH for the model with PRS and the binary family history variable etc..

sented here. Therefore, we used the single trait LT-FH++ phenotype for each of the considered phenotypes. The multi trait results are presented in Figure 4.7.

When considering multiple traits, we did not observe any difference in predictive value between the considered PRSs and binary family history variables. The model with multiple single trait LT-FH++ phenotypes had a slightly higher predictive value, which was 5.7% higher than the other two. As with the single trait prediction models, the model with both family history variables did not increase the predictive value, meaning most of the predictive value is captured by either of the family history variables. However, when considering a model with the multi trait PRS variables and either of the multi trait family history variables, we observe close to a doubling of the predictive value. This indicates that most of the predictive value caught by the PRS and family history models is different. The model with all three predictors has almost the same predictive value of the model with the PRS and either of the family history variables.




Figure 4.7: **Average out-of-sample prediction for multi trait:** Average partial  $R^2$  across 5 disorders with various prediction models. The base model includes age, sex, and 20 PCs. As the prediction is based on multi trait, PRS refers to the base model with the PRS of all considered phenotypes included. FH refers to the base model with all binary family history variables included, and FL refers to the model with all LT-FH++ variables included. Combinations of these variables are presented as PRS & FH for the model with all PRSs and all binary family history variables etc..



## Chapter 5

# Discussion

### 5.1 Paper 1 - LT-FH++

Few biobanks in the world have as detailed, curated, and complete register information linked to genetic data as iPSYCH does. Recently, there has been a trend where biobanks such as UK biobank, DeCODE, and FinnGen have started linking to registers or supplement their genetic data with questionnaires. As a result, we strongly believed that the information stored in this supplementary information can be leveraged to increase statistical power to identify causal SNPs in a GWAS setting. Family history has previously been used to generate risk scores [11, 12] or been included as a covariate in epidemiological analysis [42, 89], and as such, is a parameter many researchers are familiar with and know its potential. Similarly, an entire branch of statistics is focused on modelling time-to-event, which means many researchers are also familiar with age-of-onset and recognise its potential. Here, we proposed LT-FH++ as a way to combine family history and age-of-onset distributions with the ordinary case-control status to increase power, thereby combining two previously separated types of analysis.

Simulations show that LT-FH++ does increase statistical power in a GWAS setting over LT-FH and case-control status. The exact power increase provided by LT-FH++ over LT-FH depends on the situation the method is applied to and varies from roughly 4% to 18%. Through supplemental simulations we found that one can expect the highest increase in power with LT-FH++ over LT-FH, when cases are ascertained in the sample or in the sample's family members. The supplemental simulations have also provided valuable insight into the power difference in the real-world data analysis of UKBB and iPSYCH.

The mortality GWAS in UKBB highlights a near perfect example of LT-FH++'s potential. Death is the only guarantee in life, unlike many disorders that can be quite rare. The UKBB participants were between 40 to 69 years old at recruitment. This means many of the participant's parents have already passed or are close to their life expectancy and that the participants themselves are getting close to it. Therefore, death is prevalent among the parents and has an ever-increasing prevalence among the participants. Death has a modest prevalence in the participants, but a high prevalence among the parents. In summary, death satisfy both of the criteria for best case scenario for LT-FH++ that we identified from the simulations, namely high prevalence in the participants and/or their family history.

In iPSYCH, the conditions for both LT-FH and LT-FH++ are not nearly as favourable. The largest source of power increase provided by LT-FH and LT-FH++ are from the family history information. LT-FH++ further refines this information with the age-of-onset distributions. Due to psychiatric disorders such as ADHD not being present in ICD-8, it limits the opportunity to

diagnose many of the parents of the iPSYCH participants. This is true even though the iPSYCH participants are much younger than the UKBB participants. The design of iPSYCH also means that most affected siblings have already been selected, sequenced, and are themselves present in the data[36]. In summary, the family history seems to be lower than expected, due to the family either being sampled for iPSYCH or being too old to be easily diagnosed. However, even if an affected sibling pair is present and filtering would exclude one sibling’s genotypes, their status would still increase the liability of the remaining sibling, which would not be the case for case-control status.

Disease aetiology of the analysed phenotypes are also likely to be different. Death can have numerous sources, such as cancer, heart diseases, or accidents. Accidents are not likely to have a strong genetic signal, while cancers, heart diseases, smoking, etc. are. Some cancers and heart disease have one or more prominent genetic signals [93, 94]. On the other hand, psychiatric disorders have proven to be very polygenic, meaning there are many SNPs with a small effect size[95]. This coupled with the relatively smaller sample size of iPSYCH compared to UKBB may mean identifying genome-wide significant associations is harder, since associations with smaller effect sizes require larger sample sizes to be detected.

The essence of both LT-FH and LT-FH++ is to increase power without needing to increase the sample size by utilising additional information to estimate the underlying genetic liabilities. The availability of family history is still limited in practice for most biobanks, which limits their applicability. Unfortunately, the family history information cannot be acquired by means other than registers, questionnaires, etc. The same is not necessarily true for the CIPs. Within a biobank, information such as birth year, age-of-onset, and sex are often available to some extent. For instance, the age-of-onset may be slightly anonymised, such that the exact day or month may not be available, but a reasonable approximation is still known. The CIPs used by LT-FH++ are population representative and summarise the age-specific proportion of the considered phenotype. This means they can be used in different populations, as long as the populations and diagnosis are similar. As an example, CIPs derived from the Danish registers could be used with, e.g. other Scandinavian countries or the UK. As there are differences in diagnostic practices across countries, some care should be taken when using CIPs for other populations. For instance, if the CIPs are based on psychiatrists and the disorder of interest in a biobank is self reported.

## 5.2 Paper 2 - ADuLT

With an ever-increasing number of biobanks that are able to link electronic health records to genetic data, it is important to find the best ways to properly utilise this information. The purpose of this paper was to examine the best way to include the age-of-onset information in a GWAS setting. The gold standard for modelling time to event is a survival analysis model. However, the adoption of methods such as Cox PH have been limited for GWAS. One of the main limiting factors for such a model is the computational cost associated with the analysis. Recent advances have allowed for CoxPH models and frailty models to be used on UKBB-sized biobanks [20, 21]. Both utilise a saddle point approximation [74], as it provides a computationally efficient way to calculate p-values. Previously, such models have only been compared to other Cox models or to logistic regression, and only under the Cox PH generative model, potentially disadvantaging the logistic regression. A comparison has also not been performed when there is case ascertainment present in the data, which means either more or fewer cases than the general population. As many biobanks have some form of case ascertainment, it is important to make such a comparison.

Since a Cox PH model and a LTM are fundamentally different, we did not want to unfairly

favour one method over the other. Therefore, we performed simulations under both generative models, meaning genotypes were simulated in the same way, but the phenotype was assigned with different generative models. Analysis were then performed in each scenario and with and without case ascertainment. The LTM based methods performed the best under the LTM model, and the Cox PH performed the best under the PH model, as expected. Interestingly, we found that SPACox was disproportionately affected by case ascertainment, suffering far more than the LTM based methods. With case ascertainment, SPACox had by far the lowest power under both generative models and all prevalences considered except for the least ascertained parameter setup under the proportional hazards model. Next, we applied all three methods to the iPSYCH data, which also has a high degree of case ascertainment. We performed a GWAS on ADHD, Autism, Depression, and Schizophrenia, as all of these phenotypes are ascertained for cases. The real-world analysis was in agreement with the simulations.

Conventionally, IPW would be used to account for any form of ascertainment. As SPACox does not support IPW, we used the `coxph` function from the *survival* R package [96] for a GWAS with IPW in the simulations. We also considered a slightly smaller data set with all causal SNPs, but only 1000 null SNPs for comparison. However, it did not restore power to be on par with the LTM models. In fact, IPW did not seem to change the power in any noticeable way compared to SPACox. The test statistics used with IPW in the `coxph` function is based on a Wald test [97], which means the test statistic is the estimate divided by the standard error. When performing IPW, the estimate will remain unbiased, but estimating the standard error can be difficult [98].

In summary, we found that when no case ascertainment was present ADuLT had the highest power under the LTM and was only slightly behind SPACox under the Cox PH generative model. With case ascertainment, we found that SPACox was disproportionately affected by case ascertainment, resulting in a significantly lower power to detect causal SNPs. We observed the same loss of power in real-world analysis in iPSYCH. This leads us to conclude that using Cox PH models as they are currently implemented to identify genome-wide significant SNPs is not recommended. Researchers should instead use other methods to identify the SNPs, such as linear regression or the ADuLT phenotype with their GWAS software of choice. The Cox PH models can then be used on a set of pre-identified SNPs for subsequent analysis. Another benefit of ADuLT is the opportunity to utilise family history information as well, as presented with LT-FH++, and it has already been shown to significantly increase power. Cox PH models do not have a way to include this information in a straight forward way, further limiting its power in comparison.

### 5.3 Paper 3 - fGRS

**TODO: fGRS Discussion**

## Chapter 6

# Conclusion

The work presented in this dissertation focuses on the development, implementation, and application of what is now called LT-FH++. This model extends the previously published method called LT-FH, which is itself an extension of the classical LTM by Falconer[22, 23]. LT-FH extended the LTM to model family members for binary traits, allowing for the estimation of a genetic liability. When used as the outcome in a GWAS, the genetic liability lead to a significant power increase. LT-FH++ expanded this method even further by accounting for age-of-onset (in cases) or age (in controls), sex, and birth year in each considered individual. They are included in the model through population representative cumulative incidence proportions that are stratified by sex and birth year. By doing this, the threshold considered in the liability threshold model becomes unique for each individual. Individual thresholds have not previously been considered. Due to the fact that all individuals have a unique threshold, it was necessary to implement a computationally more efficient sampling strategy than the one used in LT-FH. As a result, LT-FH++ utilises a Gibbs sampler that efficiently samples from a truncated multivariate normal distribution with arbitrary thresholds. Furthermore, the Gibbs sampler was implemented in a way that enables computations to be performed in parallel, allowing for a better utilization of modern CPUs with many cores and high performance computing clusters.

In the first paper, “Accounting for age-of-onset and family history improves power in genome-wide association studies” [19], we considered most of the methodological development and implementation of LT-FH++. We showed that LT-FH++ performs between 4% and 18% better than LT-FH in terms of identifying the true causal associations in a simulated GWAS setup. Both LT-FH and LT-FH++ outperform the conventional case-control status and the GWAX phenotype. We assessed the performance of LT-FH++ in a non-simulated setup, by analysing mortality in the UK Biobank and four psychiatric disorders from iPSYCH. For mortality, LT-FH++ provided a large boost in power compared to LT-FH and case-control status. More precisely, we saw that LT-FH++ was able to identify 10 genome-wide significant SNPs, while LT-FH identified 2 and case-control status did not identify any. Across the four psychiatric disorders in iPSYCH, the difference between the three phenotypes was modest. There are likely several reasons for the lack of power gain over case-control status by LT-FH and LT-FH++, such as low family history prevalence and more polygenic disorders. Additional simulation studies also revealed that the mortality setup in UKBB was a near-perfect scenario for LT-FH++, as it benefits from a high prevalence in either the genotyped individuals or in the family history.

The second paper, “ADuLT: An efficient and robust time-to-event GWAS”, examined the best way to incorporate age-of-onset in a GWAS. More precisely, the paper compared ADuLT, the model underlying LT-FH++ that does not account for family history, to other time-to-event

GWAS methods. The simplest and most commonly used time-to-event GWAS method is the Cox proportional hazards model. Since the Cox PH models are computationally intensive, most implementations are unable to handle more than 100,000 individuals. We will therefore use the most computationally efficient implementation called SPACox to represent these models. We compare the performance of ADuLT to that of SPACox and case-control status in a linear regression. We simulated genotypes and assigned phenotypes and age-of-onset under both the PH model and the LTM. As expected, the LTM-based methods performed better when phenotypes were assigned with this model, while SPACox performed best when the PH model was used to assign phenotypes. However, when we introduced case ascertainment, which means that the population was downsampled in order to have an equal number of cases and controls, a disproportional loss in power was observed in connection to SPACox. Conventionally, IPW is used to account for case ascertainment. Surprisingly, the IPW did not seem to have an effect, and SPACox still performed worse than simple linear regression, even under the PH model. The same disproportionate loss of power was also observed in the analyses of the iPSYCH disorders. As a result, we do not recommend using the PH model to identify genome-wide significant SNPs. A simple linear regression or ADuLT seem to be significantly better at identifying genome-wide significant SNPs.

The third and final paper is not complete, but it has the working title, “Improving the predictive value of family history for psychiatric disorders”, and examines the predictive value of family history. Traditionally, family history is defined as a binary variable, that indicates whether the target individual has at least one family member, e.g. first degree, with the phenotype of interest. The predictive value of the binary family history indicator was compared to the PRS, as well as the LT-FH++ phenotype, where no information on the target individual was used. This means the LT-FH++ estimates the genetic liability solely based on the family history. The predictive value was assessed with the partial  $R^2$  in a linear regression model. In order to compute the partial correlation, we defined a base model including age, sex, batch, and the first 20 principal components as covariates. The base model was then extended with either of the family history phenotypes, the PRS, or any combination of these three covariates, resulting in eight different models. Averaging across the 8 considered disorders, LT-FH++ had an increased partial  $R^2$  of 19.6% compared to the model including only the PRS. The binary family history variable had a 65.2% *decrease* compared to the PRS model. The model with both the binary family history variable and the LT-FH++ phenotype had almost the same predictive value as the model including only the LT-FH++ phenotype. Interestingly, the model with the LT-FH++ phenotype and the PRS had an almost additive increase in their predictive value, indicating that they capture independent genetic signals. The model with all three predictors performed nearly identically to the model with just the LT-FH++ phenotype and the PRS, indicating that the binary family history indicator does not provide much additional information.

As most psychiatric disorders have a high genetic correlation, we also considered a regression model that included correlated phenotypes. The average prediction accuracy for of these phenotypes were higher than their single trait equivalent, but difference between LT-FH++ and the binary family history variable had largely disappeared, making both variables equally predictive. The model including both the LT-FH++ and the binary family history phenotype had nearly the same predictive power as a model accounting for either of them, meaning no new information was gained by using both. Combining the multi trait PRS with either of the family history phenotypes resulted in a model that had a predictive value close to the sum of the PRSs and the family history model’s predictive values. As before, this indicates that the genetic signal captured by the PRSs and the family history phenotypes appear to be almost independent, even when accounting for the correlation between phenotypes.

In summary, we have successfully developed, implemented, and applied the LT-FH++ method

in data sets and different ways. The LT-FH++ method provided improvements in each of the three applications that were considered, while remaining computationally efficient. Even though high quality information on family history and age-of-onset is not commonplace in all biobanks yet, we have demonstrated that the inclusion of such information can lead to better predictions and increase power in GWAS.

## Chapter 7

# Future Directions

During the dissertation, we have illustrated that the LT-FH++ (or ADuLT) phenotype has increased power in GWAS, outperformed standard survival GWAS methods when case ascertainment is present, and improved the predictive value of family history. LT-FH++ has managed to provide a computationally efficient link between the liability threshold model and survival models that can account for concepts such as censoring and family history. To the best of our knowledge, this link is a novel one that has not been examined or developed much yet. As a result, the first potential direction for future research is to examine this connection in greater detail, such that it will be possible to better understand how LT-FH++ fits in the existing survival analysis literature.

Conceptually, the genetic liability that LT-FH++ estimates share a lot of similarities with the purpose of the PRS. This relationship ought to be examined more, especially since the results from the third project of the dissertation almost showed an independent contribution from the LT-FH++ phenotype and the PRS. If they are conceptually the same, one would expect them to capture the same underlying signal, which did not seem to be the case in that project. Further examination of this relationship is therefore of particular interest. In a similar vein, if the PRS and LT-FH++ phenotype attempt to estimate the same underlying value, perhaps the PRS can be incorporated into the LT-FH++ model such that an even more accurate liability can be estimated.

Furthermore, applying LT-FH++ to new data sets is also of interest. The stay abroad during the PhD was focused on applying LT-FH++ to the FinnGen data. Unfortunately, the project was not completed during the stay and due to time constraints in the PhD, has not been completed yet. However, there are currently plans to continue this project in the future. In the Danish registers, a multi generational register is also under development, which aims to create complete family trees from 1930 and onwards, which would allow for far larger family trees than what is currently possible. LT-FH++ has already been extended to allow for more than just parents and siblings, and this multi generational register is an obvious area of application of LT-FH++.

## Chapter 8

# English Abstract

This dissertation focuses on leveraging age-of-onset information and family history to better estimate disease liability and improve statistical power in genome-wide association studies. This is achieved through the development, implementation, and application of a method called LT-FH++, which extends the previously published LT-FH method, and is based on the classical liability threshold model. LT-FH seeks to estimate a genetic liability based on family history, which has been shown to significantly increase power in GWAS. LT-FH++ extends this further by also accounting for age-of-onset in cases and age in controls, as well as sex, and birth year for all included individuals. This information is accounted for through population representative cumulative incidence proportions that are stratified by sex and birth year. This also allows the model to account for ascertainment biases when estimating disease liabilities. In practice, this leads to a threshold in the LTM that is unique to each individual. LT-FH++ utilises a computationally efficient Gibbs sampler that samples from a truncated multivariate normal distribution. The implementation is parallelizable and highly scalable for modern CPUs with many cores or high performance computing clusters.

The thesis is in three parts, where each corresponds to one paper. The first part implements LT-FH++ and benchmarks it as a method for GWAS using both extensive simulations as well as UK biobank data and iPSYCH data. The second part examines the age-dependent liability threshold model (underlying LT-FH++) as a robust and computationally efficient survival analysis GWAS method, and benchmarks it against state-of-the art approaches using simulations and the iPSYCH data. The third last part focuses on using LT-FH++ for prediction based on family history liabilities for psychiatric disorders and extends the model to allow for correlated phenotypes.



## Chapter 9

# Danish Abstract

Denne afhandling fokuserer på at udnytte familie historik og age-of-onset til at estimere en persons tilbøjelighed for en sygdom og til at forbedre statistisk styrke i GWAS. Dette opnås ved at udvikle, implementere og anvende en metode kaldet LT-FH++, som udvider den allerede udgivet LT-FH metode, som er baseret på den klassiske liability threshold model. LT-FH estimerer en genetisk tilbøjelighed til at blive syg baseret på familie historik, og det er allerede vist, at den genetiske tilbøjelighed kan forøge den statistiske styrke i GWAS. LT-FH++ udvider denne model yderligere ved også at tage højde for age-of-onset hos de sygdomsramte og alderen på kontrollerne, samt køn og fødselsår for alle inkluderet personer. Der tages højde for denne ekstra information igennem en populations repræsentativ kumulativ incidensproportion, som er stratificeret på baggrund af køn og fødselsår. Det tillader at modellen også kan tage højde for ascertainment bias når sygdomstilbøjeligheden estimeres. I praksis vil det betyde, at hver person kommer til at have en unik tærskelværdi i LTM. LT-FH++ benytter en beregningsmæssig effektiv Gibbs sampler, som sampler fra en trunkeret multivariat normalfordeling. Implementeringen kan paralleliseres og er skalerbar til at drage nytte af de mange CPU kerner, som er almindelige på moderne CPU'er, eller high performance computing clusters.

Afhandlingen består af tre dele, hvor hver del svarer til en artikel. I den første artikel blev LT-FH++ implementeret og benchmarket som en GWAS metode igennem simuleringer og anvendelse i UK biobank og iPSYCH. Den anden artikel undersøger modellen, som LT-FH++ er bygget på (age-dependent liability threshold model), som et robust og beregningsmæssig effektivt alternativ til andre state-of-the-art overlevelsesanalyse GWAS. Her benytter vi os af simuleringer og anvendelse i iPSYCH. I den tredje og sidste artikel benytter vi LT-FH++ til at estimere familie historie tilbøjeligheder for psykiatriske sygdomme og prædiktere sygdommene med disse. Vi udvider også modellen, således den er i stand til at tage højde for sygdomme. Her sammenligner vi også med en konventionel binær familie historik og PRS.

# References

1. Han, B. & Eskin, E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. *The American Journal of Human Genetics* **88**, 586–598 (2011).
2. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
3. Yengo, L. *et al.* A saturated map of common genetic variants associated with human height. *Nature* **610**, 704–712 (2022).
4. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nature genetics* **47**, 284–290 (2015).
5. Wray, N. R., Kempner, K. E., Hayes, B. J., Goddard, M. E. & Visscher, P. M. Complex trait prediction from genome data: contrasting EBV in livestock to PRS in humans: genomic prediction. *Genetics* **211**, 1131–1141 (2019).
6. Meuwissen, T. H., Hayes, B. J. & Goddard, M. Prediction of total genetic value using genome-wide dense marker maps. *genetics* **157**, 1819–1829 (2001).
7. Guttmacher, A. E., Collins, F. S. & Carmona, R. H. *The family history—more important than ever* 2004.
8. Runeson, B. & Åsberg, M. Family history of suicide among suicide victims. *American Journal of Psychiatry* **160**, 1525–1526 (2003).
9. On Hormonal Factors in Breast Cancer, C. G. *et al.* Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. *The Lancet* **358**, 1389–1399 (2001).
10. Johns, L. E. & Houlston, R. S. A systematic review and meta-analysis of familial colorectal cancer risk. *The American journal of gastroenterology* **96**, 2992–3003 (2001).
11. Kannel, W. B. Contribution of the Framingham Study to preventive cardiology. *Journal of the American College of Cardiology* **15**, 206–211 (1990).
12. Splansky, G. L. *et al.* The third generation cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination. *American journal of epidemiology* **165**, 1328–1335 (2007).
13. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
14. COMPANY en. <https://www.decode.com/company/>. Accessed: 2022-3-24. Oct. 2012.
15. Bybjerg-Grauholm, J. *et al.* The iPSYCH2015 Case-Cohort sample: updated directions for unravelling genetic and environmental architectures of severe mental disorders. *medRxiv* (2020).

16. Kurki, M. I. *et al.* FinnGen: Unique genetic insights from combining isolated population and national health register data. en. *medRxiv*, 2022.03.03.22271360 (Mar. 2022).
17. Liu, J. Z., Erlich, Y. & Pickrell, J. K. Case-control association mapping by proxy using family history of disease. *Nature genetics* **49**, 325–331 (2017).
18. Hujoel, M. L., Gazal, S., Loh, P.-R., Patterson, N. & Price, A. L. Liability threshold modeling of case-control status and family history of disease increases association power. *Nature genetics* **52**, 541–547 (2020).
19. Pedersen, E. M. *et al.* Accounting for age of onset and family history improves power in genome-wide association studies. *The American Journal of Human Genetics* **109**, 417–432 (2022).
20. Bi, W., Fritsche, L. G., Mukherjee, B., Kim, S. & Lee, S. A fast and accurate method for genome-wide time-to-event data analysis and its application to UK Biobank. *The American Journal of Human Genetics* **107**, 222–233 (2020).
21. Dey, R. *et al.* Efficient and accurate frailty model approach for genome-wide survival association analysis in large-scale biobanks. *Nature Communications* **13**, 1–13 (2022).
22. Falconer, D. S. The inheritance of liability to certain diseases, estimated from the incidence among relatives. *Annals of human genetics* **29**, 51–76 (1965).
23. Falconer, D. The inheritance of liability to diseases with variable age of onset, with particular reference to diabetes mellitus. *Annals of human genetics* **31**, 1–20 (1967).
24. Song, W. *et al.* A selection pressure landscape for 870 human polygenic traits. *Nature Human Behaviour* **5**, 1731–1743 (2021).
25. Pardiñas, A. F. *et al.* Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nature genetics* **50**, 381–389 (2018).
26. Esteller-Cucala, P. *et al.* Genomic analysis of the natural history of attention-deficit/hyperactivity disorder using Neanderthal and ancient Homo sapiens samples. *Scientific reports* **10**, 1–11 (2020).
27. Han, J. *et al.* A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. *PLoS genetics* **4**, e1000074 (2008).
28. Bergen, S. E. & Petryshen, T. L. Genome-wide association studies of schizophrenia: does bigger lead to better results? *Current opinion in psychiatry* **25**, 76–82 (2012).
29. Badano, J. L. & Katsanis, N. Beyond Mendel: an evolving view of human genetic disease transmission. *Nature Reviews Genetics* **3**, 779–789 (2002).
30. Pedersen, C. B. The Danish civil registration system. *Scandinavian journal of public health* **39**, 22–25 (2011).
31. Lynge, E., Sandegaard, J. L. & Rebolj, M. The Danish national patient register. *Scandinavian journal of public health* **39**, 30–33 (2011).
32. Mors, O., Pertou, G. P. & Mortensen, P. B. The Danish psychiatric central research register. *Scandinavian journal of public health* **39**, 54–57 (2011).
33. Nørgaard-Pedersen, B. & Hougaard, D. M. Storage policies and use of the Danish Newborn Screening Biobank. *Journal of Inherited Metabolic Disease: Official Journal of the Society for the Study of Inborn Errors of Metabolism* **30**, 530–536 (2007).
34. Hansen, S. N., Overgaard, M., Andersen, P. K. & Parner, E. T. Estimating a population cumulative incidence under calendar time trends. *BMC medical research methodology* **17**, 1–10 (2017).

35. Andersen, P. K., Geskus, R. B., De Witte, T. & Putter, H. Competing risks in epidemiology: possibilities and pitfalls. *International journal of epidemiology* **41**, 861–870 (2012).
36. Pedersen, C. B. *et al.* The iPSYCH2012 case-cohort sample: new directions for unravelling genetic and environmental architectures of severe mental disorders. *Molecular psychiatry* **23**, 6–14 (2018).
37. Biobank, U. Genotyping and quality control of UK Biobank, a large-scale, extensively phenotyped prospective resource, 2016. [https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/genotyping\\\_qc.pdf](https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/genotyping\_qc.pdf) (2015) (2015).
38. Van Hout, C. V. *et al.* Exome sequencing and characterization of 49,960 individuals in the UK Biobank. *Nature* **586**, 749–756 (2020).
39. Website <https://www.ukbiobank.ac.uk/enable-your-research/about-our-data/genetic-data>. Accessed: 2022-12-06. 2022.
40. Website <https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/CancerLinkage.pdf>. Accessed: 2022-12-06. 2022.
41. Website
42. Schendel, D. *et al.* Evaluating the interrelations between the autism polygenic score and psychiatric family history in risk for autism. *Autism Research* **15**, 171–182 (2022).
43. Cochran, W. G. Some methods for strengthening the common  $\chi^2$  tests. *Biometrics* **10**, 417–451 (1954).
44. Armitage, P. Tests for Linear Trends in Proportions and Frequencies. *Biometrics* **11**, 375–386. ISSN: 0006341X, 15410420. <http://www.jstor.org/stable/3001775> (2022) (1955).
45. Balding, D. J. A tutorial on statistical methods for population association studies. *Nature reviews genetics* **7**, 781–791 (2006).
46. Zeng, P. *et al.* Statistical analysis for genome-wide association study. *Journal of biomedical research* **29**, 285 (2015).
47. Privé, F., Vilhjálmsson, B. J., Aschard, H. & Blum, M. G. Making the most of clumping and thresholding for polygenic scores. *The American Journal of Human Genetics* **105**, 1213–1221 (2019).
48. Sikorska, K., Lesaffre, E., Groenen, P. F. & Eilers, P. H. GWAS on your notebook: fast semi-parallel linear and logistic regression for genome-wide association studies. *BMC bioinformatics* **14**, 1–11 (2013).
49. De Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS computational biology* **11**, e1004219 (2015).
50. Pirinen, M., Donnelly, P. & Spencer, C. C. Efficient computation with a linear mixed model on large-scale data sets with applications to genetic studies. *The Annals of Applied Statistics*, 369–390 (2013).
51. Abdellaoui, A. *et al.* Association between autozygosity and major depression: Stratification due to religious assortment. *Behavior genetics* **43**, 455–467 (2013).
52. Whole-genome sequence variation, population structure and demographic history of the Dutch population. *Nature genetics* **46**, 818–825 (2014).
53. Marees, A. T. *et al.* A tutorial on conducting genome-wide association studies: Quality control and statistical analysis. *International journal of methods in psychiatric research* **27**, e1608 (2018).

54. Hamer, D. H. Beware the chopsticks gene. *Molecular psychiatry* **5**, 11–13 (2000).
55. Price, A. L. *et al.* Principal components analysis corrects for stratification in genome-wide association studies. *Nature genetics* **38**, 904–909 (2006).
56. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population stratification in genome-wide association studies. *Nature reviews genetics* **11**, 459–463 (2010).
57. Privé, F., Luu, K., Blum, M. G., McGrath, J. J. & Vilhjálmsson, B. J. Efficient toolkit implementing best practices for principal component analysis of population genetic data. *Bioinformatics* **36**, 4449–4457 (2020).
58. Helgason, A., Yngvadottir, B., Hrafnkelsson, B., Gulcher, J. & Stefánsson, K. An Icelandic example of the impact of population structure on association studies. *Nature genetics* **37**, 90–95 (2005).
59. Atkinson, E. G. *et al.* Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and to boost power. *Nature genetics* **53**, 195–204 (2021).
60. Astle, W. & Balding, D. J. Population structure and cryptic relatedness in genetic association studies. *Statistical Science* **24**, 451–471 (2009).
61. Voight, B. F. & Pritchard, J. K. Confounding from cryptic relatedness in case-control association studies. *PLoS genetics* **1**, e32 (2005).
62. Sillanpää, M. J. Overview of techniques to account for confounding due to population stratification and cryptic relatedness in genomic data association analyses. *Heredity* **106**, 511–519 (2011).
63. Yu, J. *et al.* A unified mixed-model method for association mapping that accounts for multiple levels of relatedness. *Nature genetics* **38**, 203–208 (2006).
64. Kang, H. M. *et al.* Efficient control of population structure in model organism association mapping. *Genetics* **178**, 1709–1723 (2008).
65. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *The American Journal of Human Genetics* **88**, 76–82 (2011).
66. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, s13742–015 (2015).
67. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *The American journal of human genetics* **81**, 559–575 (2007).
68. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**, 2867–2873 (2010).
69. Rice, T. K., Schork, N. J. & Rao, D. Methods for handling multiple testing. *Advances in genetics* **60**, 293–308 (2008).
70. Pe’er, I., Yelensky, R., Altshuler, D. & Daly, M. J. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. *Genetic Epidemiology: The Official Publication of the International Genetic Epidemiology Society* **32**, 381–385 (2008).
71. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nature genetics* **50**, 1335–1341 (2018).
72. Ma, C., Blackwell, T., Boehnke, M., Scott, L. J. & Investigators, G. Recommended joint and meta-analysis strategies for case-control association testing of single low-count variants. *Genetic epidemiology* **37**, 539–550 (2013).

73. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nature genetics* **53**, 1097–1103 (2021).
74. Daniels, H. E. Saddlepoint approximations in statistics. *The Annals of Mathematical Statistics*, 631–650 (1954).
75. Kuonen, D. Miscellanea. Saddlepoint approximations for distributions of quadratic forms in normal variables. *Biometrika* **86**, 929–935 (1999).
76. Andersen, P. K., Borgan, O., Gill, R. D. & Keiding, N. *Statistical models based on counting processes* (Springer Science & Business Media, 2012).
77. Website <https://catalogofbias.org/biases/>. Accessed: 2022-11-29. 2017.
78. Koul, H, Susarla, V. & Van Ryzin, J. Regression analysis with randomly right-censored data. *The Annals of statistics*, 1276–1288 (1981).
79. Seaman, S. R. & White, I. R. Review of inverse probability weighting for dealing with missing data. *Statistical methods in medical research* **22**, 278–295 (2013).
80. Svishcheva, G. R., Axenovich, T. I., Belonogova, N. M., Van Duijn, C. M. & Aulchenko, Y. S. Rapid variance components-based method for whole-genome association analysis. *Nature genetics* **44**, 1166–1170 (2012).
81. Lippert, C. *et al.* FaST linear mixed models for genome-wide association studies. *Nature methods* **8**, 833–835 (2011).
82. Aschard, H., Vilhjálmsson, B. J., Joshi, A. D., Price, A. L. & Kraft, P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. *The American Journal of Human Genetics* **96**, 329–339 (2015).
83. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature genetics* **47**, 291–295 (2015).
84. Weissbrod, O., Lippert, C., Geiger, D. & Heckerman, D. Accurate liability estimation improves power in ascertained case-control studies. *Nature methods* **12**, 332–334 (2015).
85. Wilhelm, S. *Gibbs sampler for the truncated multivariate normal distribution* 2015.
86. Wilhelm, S. & Manjunath, B. tmvtnorm: A package for the truncated multivariate normal distribution. *sigma* **2**, 1–25 (2010).
87. Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics using MTAG. *Nature genetics* **50**, 229–237 (2018).
88. Kragh Andersen, P. *et al.* Analysis of time-to-event for observational studies: Guidance to the use of intensity models. *Statistics in medicine* **40**, 185–211 (2021).
89. Ejlskov, L. *et al.* Prediction of autism risk from family medical history data using machine learning: a national cohort study from Denmark. *Biological Psychiatry Global Open Science* **1**, 156–164 (2021).
90. Williams, R. R. *et al.* Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). *The American journal of cardiology* **87**, 129–135 (2001).
91. Schork, A. J. *et al.* A genome-wide association study of shared risk across psychiatric disorders implicates gene regulation during fetal neurodevelopment. *Nature neuroscience* **22**, 353–361 (2019).
92. Hyman, S. E. The diagnosis of mental disorders: the problem of reification. *Annual review of clinical psychology* **6**, 155–179 (2010).

93. Koyama, S. *et al.* Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. *Nature genetics* **52**, 1169–1177 (2020).
94. Marioni, R. E. *et al.* GWAS on family history of Alzheimer’s disease. *Translational psychiatry* **8**, 1–7 (2018).
95. Gandal, M. J. *et al.* Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. *Science* **359**, 693–697 (2018).
96. Therneau, T. M. *A Package for Survival Analysis in R* (2020). <https://CRAN.R-project.org/package=survival>.
97. Therneau, T. *A package for survival analysis in R* (2022). <https://cran.r-project.org/web/packages/survival/vignettes/survival.pdf> (2022).
98. Austin, P. C. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. *Statistics in medicine* **35**, 5642–5655 (2016).

# Appendices



# Appendix A

## Paper 1 - LT-FH++

EM Pedersen, E Agerbo, O Plana-Ripoll, J Grove, JW Dreier, KL Musliner, M Bækvad-Hansen, G Athanasiadis, A Schork, D Demontis, J Bybjerg-Grauholm, DM Hougaard, T Werge, M Nordentoft, O Mors, S Dalsgaard, J Christensen, AD Børglum, PB Mortensen, JJ McGrath, F Privé, BJ Vilhjálmsón. Accounting for age-of-onset and family history improves power in genome-wide association studies. *American Journal of Human Genetics*, 109: 417-432.

# Accounting for age of onset and family history improves power in genome-wide association studies

## Authors

Emil M. Pedersen, Esben Agerbo,  
Oleguer Plana-Ripoll, ..., John J. McGrath,  
Florian Privé, Bjarni J. Vilhjálmsson

## Correspondence

[bjv@econ.au.dk](mailto:bjv@econ.au.dk) (B.J.V.),  
[emp@ph.au.dk](mailto:emp@ph.au.dk) (E.M.P.)



Pedersen et al., 2022, *The American Journal of Human Genetics* 109, 417–432  
March 3, 2022 © 2022 The Authors.  
<https://doi.org/10.1016/j.ajhg.2022.01.009>

## Appendix B

### Paper 2 - ADuLT

EM Pedersen, E Agerbo, O Plana-Ripoll, J Steinbach, MD Krebs, DM Hougaard, T Werge, M Nordentoft, A Børglum, KL Musliner, A Ganna, AJ Schork, PB Mortensen, JJ McGrath, F Privé, BJ Vilhjálmsón. ADuLT: An efficient and robust time-to-event GWAS. medRxiv, doi: <https://doi.org/10.1101/2022.08.11.22278618> [Under review]

# ADuLT: An efficient and robust time-to-event GWAS

Emil M. Pedersen<sup>1,2,\*</sup>, Esben Agerbo<sup>1,2,3</sup>, Oleguer Plana-Ripoll<sup>1,4</sup>, Jette Steinbach<sup>1</sup>, Morten Dybdahl Krebs<sup>5</sup>, David M. Hougaard<sup>6</sup>, Thomas Werge<sup>5,7,8</sup>, Merete Nordentoft<sup>2,18</sup>, Anders D. Børghlum<sup>2,9,10</sup>, Katherine L. Musliner<sup>1,11,12</sup>, Andrea Ganna<sup>13</sup>, Andrew J. Schork<sup>5,8,14</sup>, Preben B. Mortensen<sup>1,2</sup>, John J. McGrath<sup>1,15,16</sup>, Florian Privé<sup>1,2,†</sup>, Bjarni J. Vilhjálmsson<sup>1,2,17,†,\*</sup>

<sup>1</sup>National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark.

<sup>2</sup>Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus, Denmark.

<sup>3</sup>Centre for Integrated Register-based Research at Aarhus University, Aarhus, Denmark.

<sup>4</sup>Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.

<sup>5</sup>Institute of Biological Psychiatry, Mental Health Center - Sct Hans, Copenhagen University Hospital – Mental Health Services CPH, Copenhagen, Denmark.

<sup>6</sup>Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.

<sup>7</sup>Department of Clinical Sciences, Copenhagen University.

<sup>8</sup>Section for Geogenetics, GLOBE Institute, Faculty of Health and Medical Science, Copenhagen University.

<sup>9</sup>Department of Biomedicine and iSEQ Centre, Aarhus University, Aarhus, Denmark.

<sup>10</sup>Center for Genomics and Personalized Medicine, CGPM, Aarhus University, Aarhus, Denmark.

<sup>11</sup>Department of Affective Disorders, Aarhus University Hospital-Psychiatry, Aarhus, Denmark.

<sup>12</sup>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

<sup>13</sup>Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.

<sup>14</sup>Neurogenomics Division, The Translational Genomics Research Institute (TGEN), Phoenix, AZ, USA.

<sup>15</sup>Queensland Brain Institute, University of Queensland, St Lucia, Queensland, Australia.

<sup>16</sup>Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, Queensland, Australia.

<sup>17</sup>Bioinformatics Research Centre, Aarhus University, Denmark.

<sup>18</sup>CORE- Copenhagen Centre for Research in Mental Health, Mental Health Center - Copenhagen, Copenhagen University Hospital – Mental Health Services CPH, Copenhagen, Denmark.

<sup>†</sup>Contributed equally.

\*Corresponding authors: emp@ncrr.au.dk, bjv@ncrr.au.dk

## Abstract

Proportional hazards models have previously been proposed to analyse time-to-event phenotypes in genome-wide association studies (GWAS). While proportional hazards models have many useful applications, their ability to identify genetic associations under different generative models where ascertainment is present in the analysed data is poorly understood. This includes widely used study designs such as case-control and case-cohort designs (e.g. the iPSYCH study design) where cases are commonly ascertained.